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Clinical Importance of the Drug interaction Between Statins and CYP3A4
Inhibitors
Abstract
Statins reduce the risk of major coronary outcomes and all cause mortality. They are generally well
tolerated, but are associated with uncommon but serious adverse events. Pharmacokinetic studies show
statins metabolized by the CYP3A4 isoenzyme (statin 3A4 substrates) are susceptible to drug
interactions when concomitantly administered with drugs that inhibit the CYP3A4 isoenzyme (CYP3A4
inhibitors) - potentially increasing the risk for adverse events. Studies to evaluate the clinical importance
of the statin-CYP3A4 inhibitor interaction are limited to anecdotal findings. This research endeavored to
evaluate the clinical importance of the statin-CYP3A4 inhibitor drug interaction in two empiric
investigations and a methodologic study.
The preliminary empiric study was an analysis of spontaneous rhabdomyolysis reports. It showed an
increased rhabdomyolysis reporting rate for simvastatin (a statin 3A4 substrate) but not for pravastatin (a
statin non-3A4 substrate) with a concomitant CYP3A4 inhibitor. Substantial internal validity limitations,
inherent in spontaneous reporting analyses, warranted additional research.
To further assess the clinical importance of this drug interaction, we evaluated the validity of the
multinomial propensity score as a confounding adjustment method in a simulated drug interaction study.
The results from the simulation study provided support for using the multinomial propensity score in the
second empiric study. The results showed the multinomial propensity score reduced bias, had greater
coverage probability, and increased precision compared to binary propensity score methods.
Investigators studying multinomial exposures, such as drug interactions, should consider the multinomial
propensity score for confounding adjustment.
The second empiric study was a large retrospective cohort study. The objective was to evaluate the
hazard of muscle toxicity, renal dysfunction, and hepatic dysfunction among patients exposed to statin
3A4 substrates (atorvastatin and simvastatin) compared to statin non-3A4 substrates (fluvastatin,
pravastatin, and rosuvastatin) with and without CYP3A4 inhibitor concomitancy. We found no overall
increased hazard of muscle toxicity, renal dysfunction, or hepatic dysfunction associated with statin 3A4
substrates compared to statin non-3A4 substrates with versus without a concomitant CYP3A4 inhibitor.
Given the magnitude and validity of this investigation, the drug interaction between statins and CYP3A4
inhibitors therefore does not represent a substantial public health concern.
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ABSTRACT
CLINICAL IMPORTANCE OF THE DRUG INTERACTION BETWEEN STATINS AND CYP3A4
INHIBITORS
Christopher G. Rowan
Supervisor: Brian L. Strom MD, MPH
Statins reduce the risk of major coronary outcomes and all cause mortality. They are
generally well tolerated, but are associated with uncommon but serious adverse events.
Pharmacokinetic studies show statins metabolized by the CYP3A4 isoenzyme (statin 3A4
substrates) are susceptible to drug interactions when concomitantly administered with drugs that
inhibit the CYP3A4 isoenzyme (CYP3A4 inhibitors) - potentially increasing the risk for adverse
events. Studies to evaluate the clinical importance of the statin-CYP3A4 inhibitor interaction are
limited to anecdotal findings. This research endeavored to evaluate the clinical importance of the
statin-CYP3A4 inhibitor drug interaction in two empiric investigations and a methodologic study.
The preliminary empiric study was an analysis of spontaneous rhabdomyolysis reports. It
showed an increased rhabdomyolysis reporting rate for simvastatin (a statin 3A4 substrate) but
not for pravastatin (a statin non-3A4 substrate) with a concomitant CYP3A4 inhibitor. Substantial
internal validity limitations, inherent in spontaneous reporting analyses, warranted additional
research.
To further assess the clinical importance of this drug interaction, we evaluated the validity of
the multinomial propensity score as a confounding adjustment method in a simulated drug
interaction study. The results from the simulation study provided support for using the multinomial
propensity score in the second empiric study. The results showed the multinomial propensity
score reduced bias, had greater coverage probability, and increased precision compared to
binary propensity score methods. Investigators studying multinomial exposures, such as drug
interactions, should consider the multinomial propensity score for confounding adjustment.
The second empiric study was a large retrospective cohort study. The objective was to
evaluate the hazard of muscle toxicity, renal dysfunction, and hepatic dysfunction among patients
exposed to statin 3A4 substrates (atorvastatin and simvastatin) compared to statin non-3A4
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substrates (fluvastatin, pravastatin, and rosuvastatin) with and without CYP3A4 inhibitor
concomitancy. We found no overall increased hazard of muscle toxicity, renal dysfunction, or
hepatic dysfunction associated with statin 3A4 substrates compared to statin non-3A4 substrates
with versus without a concomitant CYP3A4 inhibitor. Given the magnitude and validity of this
investigation, the drug interaction between statins and CYP3A4 inhibitors therefore does not
represent a substantial public health concern.
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DISSERTATION INTRODUCTION
Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are
extremely effective in the treatment of dyslipidemia. They have been shown to reduce the risk of
major coronary outcomes and all cause mortality.1, 2 While statins are well tolerated by the vast
majority of patients, they are associated with infrequent muscle, renal, and hepatic adverse
events.3-9 Statin associated muscle and renal toxicity occur on a continuum from minor myalgias
and proteinuria to severe myositis, renal failure, and fatal rhabdomyolysis.10-12 Statin associated
hepatic toxicity is characterized by transaminitis and rarely serious hepatic dysfunction or hepatic
failure.13, 14 Clinical trials, case reports, and observational studies show these adverse events are
associated with all marketed statins.9, 15-17 While the incidence of serious statin adverse events is
low, muscle toxicity is a leading cause of statin discontinuation - particularly among patients
treated with high-potency statin therapy.18,

19

It has been shown that statin-related adverse

events occur in a dose dependent manner.

It has been hypothesized that they may be

exacerbated by pharmacokinetic (PK) statin-drug interactions that increase statin system
exposure.8, 15, 20 17, 21 22-25
However, not all statins have the same drug interaction potential.

The unique

physiochemical property of each statin makes certain statins more likely to interact with
concomitant medications. Of particular importance is the drug interaction between statins and
drugs that inhibit the CYP3A4 metabolic pathway. The CYP3A4 isoenzyme is the most prevalent
isoenzyme in the cytochrome P450 enzyme system. The CYP3A4 isoenzyme metabolizes more
than 50% of all marketed pharmaceuticals.26 Statins that undergo phase I metabolism by the
CYP3A4 isoenzyme are referred to as statin 3A4 substrates. Statins that do no use the CYP3A4
isoenzyme metabolic pathway are referred to as statin non-3A4 substrates. This investigation
focuses on statin phase I metabolic inhibition, specifically the clinical importance of the drug
interaction between statins and concomitant drugs which inhibit the CYP3A4 isoenzyme
(CYP3A4 inhibitors). CYP3A4 inhibitors prevent CYP3A4 isoenzymes from metabolizing other
drugs (e.g., statin 3A4 substrates). As serious statin adverse events are potency and plasma
concentration related, it is recognized that plasma levels of statins 3A4 substrates may increase
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with concomitant administered of CYP3A4 inhibitors.27 Currently marketed pharmaceuticals that
are CYP3A4 inhibitors are commonly used. They include calcium channel blockers, H2 receptor
antagonists, antibiotics, antifungals, antidepressants, antiretrovirals, and immunosuppresants.28
The purpose of this investigation is to study the clinical importance of the drug interaction
between statins and CYP3A4 inhibitors. Given the physiochemical properties, drug interaction
potential, and prior research, we hypothesized an increased relative hazard for statin 3A4
substrates compared to statin non-3A4 substrates with CYP3A4 inhibitor concomitancy. Studies
to quantify the hazard of statin-related adverse events for different statins (with different
metabolism) with CYP3A4 inhibitor concomitancy have not been conducted.
We conducted two empiric investigations and a methodologic study to evaluate the clinical
importance of the drug interaction between statins and CYP3A4 inhibitors. The first empiric study
uses spontaneous reports of rhabdomyolysis associated with simvastatin and pravastatin to
determine if the CYP3A4 mediated drug interaction results in a selective increase in
rhabdomyolysis reporting rates based on different statin metabolic pathways. Given the
aforementioned physiochemical characteristics of each statin, we hypothesize an increased risk
for simvastatin, but not for pravastatin, with CYP3A4 inhibitor concomitancy. The project title is:
Clinical importance of the drug interaction between statins and CYP3A inhibitors - analysis of
spontaneous reports of rhabdomyolysis. Its specific aim is: to determine if the CYP3A4 mediated
drug interaction results in a selective increase in spontaneous rhabdomyolysis reporting rates
based on different statin metabolic pathways. The study’s hypothesis is: because of the potential
increased statin exposure when a statin 3A4 substrate is concomitantly prescribed with a 3A4
inhibitor, there will be greater spontaneous rhabdomyolysis reporting compared to patients
concomitantly prescribed a statin non-3A4 substrate and a 3A4 inhibitor.
The methodologic study is a simulation study to evaluate propensity score methods in the
setting of a drug-drug interaction study.

In drug-drug interaction studies, such as with

aforementioned empiric studies of statins and CYP3A4 inhibitors, there may be more than two
non-ordered exposure categories. No applied methodologic research using simulations to
evaluate different propensity score methods in multiple, non-ordered exposure categories have
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been published. This study evaluated relative bias and coverage probability associated with
different binary and multinomial propensity score methods. Researchers studying drug
interactions may find this research informative to guide their confounding adjustment method. By
evaluating each propensity score method under different scenarios, we intended to provide drugdrug interaction researchers with a broadly applicable tool that will guide their choice of PS
method.

Specifically, the title is:

A comparison of multinomial and binary propensity score

methods in a drug-drug interaction study. Its specific aim is to use Monte Carlo simulation to
compare bias, precision, and coverage probability of multinomial and multiple binary propensity
score methods in the setting of drug-drug interaction studies. The study’s hypothesis is: the
multinomial propensity score will reduce bias, increase precision, and have better empiric
coverage than multiple different binary propensity score methods.
The second empiric study endeavors to evaluate the clinical importance of the drug
interaction between statins and CYP3A4 inhibitors in a large retrospective cohort study using a
validated electronic medical record database. In three separate cohort studies, we evaluated the
relative hazard of (i) muscle toxicity, (ii) kidney dysfunction, and (iii) hepatic dysfunction
associated with statin 3A4 substrates compared to statin non-3A4 substrates with CYP3A4
inhibitor concomitancy. The project title is: Clinical importance of the drug interaction between
statins and CYP3A4 inhibitors - THIN Cohort study. Its specific aim is: to compare the relative
hazard of muscle toxicity, kidney dysfunction, and hepatic dysfunction following concomitant
therapy with a: [statin CYP3A4 substrate plus a CYP3A4 inhibitor] vs. [statin non-CYP3A4
substrate plus a CYP3A4 inhibitor]. The study’s hypothesis is: because of the potential increased
statin exposure when a statin CYP3A4 substrate is concomitantly prescribed with a CYP3A4
inhibitor, there will be greater relative hazard of muscle toxicity, renal dysfunction, and hepatic
dysfunction compared to patients concomitantly prescribed a statin non-CYP3A4 substrate and a
CYP3A4 inhibitor.
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PROJECT 1: CLINICAL IMPORTANCE OF THE DRUG INTERACTION BETWEEN STATINS
AND CYP3A4 INHIBITORS - ANALYSIS OF SPONTANEOUS REPORTS OF
RHABDOMYOLYSIS (AERS)
Title of the paper: Rhabdomyolysis reports show interaction between simvastatin and CYP3A4
inhibitors
Names of the Authors:
Christopher Rowan, B.S.1
Allen D. Brinker, M.D., M.S.2
Parivash Nourjah, Ph.D.2
Jennie Chang, Pharm.D.2
Andrew Mosholder, M.D., M.P.H.2
Jeffrey S. Barrett, Ph.D., FCP3
Mark Avigan, M.D., C.M.2
Names of the Institutions:
University of Pennsylvania School of Medicine
Center for Clinical Epidemiology and Biostatistics

1

2

Division of Drug Risk Evaluation, Office of Surveillance and Epidemiology, Center for Drug
Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland
3

Laboratory for Applied PK/PD, Clinical Pharmacology & Therapeutics Division
The Children's Hospital of Philadelphia
Contact information for the corresponding author:
Christopher Rowan
University of Pennsylvania School of Medicine
Center for Clinical Epidemiology and Biostatistics
Room 108, Blockley Hall
423 Guardian Drive
Philadelphia, Pennsylvania, 19104
E-mail: crowan@mail.med.upenn.edu

Five key points:
1. We studied spontaneous reports of rhabdomyolysis associated simvastatin, a CYP3A4
substrate, and pravastatin, a non-CYP3A4 substrate, for evidence of CYP3A4 interaction.
2. We found 3 out of 25 pravastatin reports and 56 out of 118 simvastatin reports were associated
with a concomitant CYP3A4 inhibitor
3. Fifteen percent of pravastatin and 12.5 percent of simvastatin prescriptions were concomitantly
prescribed with a CYP3A inhibitor.
4. The adverse event reporting rate ratios for rhabdomyolysis (statin w/CYP3A4 inhibitor vs. statin
w/o CYP3A4 inhibitor) were 0.77 and 6.34 for pravastatin and simvastatin respectively.
5. The comparison of reporting rate ratios (simvastatin/pravastatin) suggests effect modification
by CYP3A4 inhibitor as predicted in FDA approved labeling for simvastatin.
Requests for reprints should be sent to:
crowan@mail.med.upenn.edu
Conflict of Interest: None declared
Disclaimer: The views expressed are those of the authors and do not necessarily represent those
of the Food and Drug Administration or imply its endorsement.
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ABSTRACT
Purpose: To assess spontaneous reports of rhabdomyolysis associated with simvastatin and
pravastatin for evidence of concomitant CYP3A4 inhibitor interaction. Clinical trial results
advocate for the use of cholesterol lowering in high-risk patients including diabetics and the
elderly. Given the association between advancing age, metabolic, and cardiovascular disease,
many patients are treated with concomitant medications upon statin initiation. Although statins are
generally safe, minor and severe adverse reactions arise, especially when given to patients
taking concomitant medications that inhibit the statin clearance and lead to increased statin
plasma concentration.
Methods: We conducted a comparative case series of rhabdomyolysis reports associated with
simvastatin and pravastatin. Domestic spontaneous reports were obtained from the FDA's
Adverse Event Reporting System (AERS). Drug utilization data were obtained from IMS HEALTH
and the National Ambulatory Medical Care Survey (NAMCS). Adverse event reporting rates
(AER) and ratios (AERR) of rhabdomyolysis associated with simvastatin and pravastatin stratified the presence and absence of a concomitant CYP3A4 inhibitor concomitancy were
determined.
Results: Stratification by CYP3A4 inhibitor concomitancy did not change the rhabdomyolysis AER
for pravastatin with versus without a CYP3A4 inhibitor (2.4 cases and 3.1 cases per 10 million Rx,
respectively). However, stratification of simvastatin reports with versus without a concomitant
CYP3A4 inhibitor resulted in a rhabdomyolysis AER of 38.4 and 6.0 cases per 10 million Rx. The
corresponding AERR with versus without a CYP3A4 inhibitor was 0.77 for pravastatin and 6.43
for simvastatin.
Conclusions:
Spontaneous adverse event reports provide evidence of increased risk for rhabdomyolysis based
on the interaction between simvastatin and selected CYP3A4 inhibitors.
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INTRODUCTION
Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are
extremely effective in the treatment of dyslipidemias.29,

30

They are well tolerated by the vast

majority of patients, but are infrequently associated with muscle related toxicity. Statin associated
muscle toxicity occurs on a continuum from minor myalgias to potentially fatal rhabdomyolysis.10
Though rare, rhabdomyolysis has been reportedly associated with all currently marketed statins.
Postmarketing reports of rhabdomyolysis resulted in the suspension of cerivastatin marketing,
likely due to a drug-drug interaction.23 However, because statins have variable physiochemical
properties, certain statins may be more or less likely to interact with concomitant medications.
Due to high affinity and selectivity for the HMG-CoA reductase enzyme, statins have little
potential to alter the pharmacokinetics of other drugs.31 However, the unique pharmacokinetic
(PK) characteristics of each statin may substantially impact their susceptibility to be modified by
concomitant medications.27 The PK differences between statins include: solubility, phase I and II
metabolism, utilization of hepatic transporters, formation of active metabolites, bioavailability,
protein binding, and excretion. Importantly, simvastatin (SV) and lovastatin (LV) are administered
as lactone pro-drugs while the other statins are administered as β-hydroxy acids. SV and LV
lactone undergo hydrolysis in the plasma, intestinal mucosa, and liver to form active β-hydroxy
acids.32-36 One PK characteristic shared by all statins is extensive first pass hepatic extraction.
Hepatic extraction occurs by two primary mechanisms - active transport and passive
diffusion. Organic anion transporting polypeptide (OATP) is the primary membrane protein which
actively transports hydrophilic statins pravastatin (PV) and rosuvastatin (RV) from portal
circulation into the hepatocyte (influx). The lipophilic statins atorvastatin (AV), CV, fluvastatin
(FV), LV, and SV enter mainly by passive diffusion; however, the acid forms of these statins also
utilize active transport mechanisms.27, 37-40
Following entry into the hepatocyte each statin undergoes a unique cascade of metabolic
and non-metabolic processes which ultimately results in cholesterol biosynthesis inhibition and
statin elimination. The metabolic processes include phase I oxidation (mediated by cytochrome
P450 (CYP) isoenzymes) and phase II glucuronidation (mediated by UDP glucuronosyl
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transferase (UGT)). The CYP isoenzymes responsible for phase I statin metabolism are 3A4,
2C8, 2C9, and 2C19. Atorvastatin, LV, and SV are oxidized by the CYP3A4 isoenzyme to form
both active and inactive metabolites.41, 42 Cerivastatin (CV) is oxidized by CYP2C8 and to a lesser
extent CYP3A4.43 Fluvastatin (FV) is oxidized by CYP2C9.39, 43 Pravastatin (PV) has no phase I
metabolism and is minimally metabolized by phase II glucuronidation. Rosuvastatin (RV) also has
negligible phase I metabolism (by CYP2C9 and CYP2C19) and is primarily eliminated as the
unchanged parent compound.36, 44
Following hepatocyte entry and metabolism (phase I and II), statins exert their cholesterol
inhibitory effect and are subsequently eliminated. However, a varying proportion of statin reaches
systemic circulation, by efflux transport and passive diffusion.27, 37, 38 The efflux transport proteins:
P-glycoprotein (P-gp) and multidrug resistance associated protein 2 (MRP2), are believed to
affect the disposition, bioavailability and elimination of all statins - primarily in the acid form.45 For
most statins, elimination occurs through biliary excretion, PV is partially eliminated by renal
excretion. Inhibition of statin metabolism (phase I or II) and/or active membrane transporters
(influx or efflux) may result in elevated plasma concentrations and has the potential to increase
the risk for statin-related adverse events.
Gemfibrozil (GEM) and cyclosporine (CSA) have been shown to interact with statins via both
metabolic and hepatic transport pathways. Shitara et al showed the drug interaction between
GEM and CV occurred via GEM inhibiting CV hepatic uptake (via OATP) and oxidation (via
CYP2C8).46 Similarly, CSA has been shown to inhibit hepatic uptake (OATP), efflux transporters
(P-gp and MRP2), and oxidation (via CYP3A4).47 Olbricht et al showed a 5 and 20 fold increase
in area under the curve (AUC) for PV and LV respectively in kidney transplant patients treated
with CSA.48 Given PV is not a CYP3A4 substrate, the increased AUC is the likely result of
transporter mediated inhibition.
This investigation focuses on statin phase I metabolic inhibition, specifically the drug
interaction between statins and concomitant drugs which inhibit CYP3A4 mediated metabolism
(CYP3A4 inhibitors).

As serious statin adverse events are dose and plasma concentration

related, it is recognized that plasma levels of statins oxidized by the CYP3A4 isoenzyme may

7

increase when these statins are concomitantly administered with CYP3A4 inhibitors.41, 49, 50 Many
commonly used pharmaceuticals are CYP3A4 inhibitors.28 Some of the drug classes that include
CYP3A4 inhibitors are calcium channel blockers, antibiotics, antifungals, antidepressants,
anitretrovirals, and immunosuppresants.28
The CYP3A4 isoenzyme metabolizes more than 50% of marketed drugs.26

A recent

investigation showed 25% of new statin initiators received a concomitant CYP3A4 inhibitor in the
first year of statin therapy.51 Case reports, risk-factor models, and clinical trials have shown
concomitant administration of statins and CYP3A4 inhibitors may increase the risk for
rhabdomyolysis.52-54 Because of the potential increased risk, some statin product labels warn
against concomitant administration with CYP3A4 inhibitors.
To study the clinical impact of this association we studied two statins with different Phase I
metabolism, but similar hepatic transport mechanisms. SV (a CYP3A4 substrate) was chosen as
the object drug and PV (a non-CYP3A4 substrate) as the comparator object drug. While the
phase I metabolic pathways for SV and PV are different, both statins should be similarly impacted
by influx and efflux hepatic transporters (via OATP, P-gp, and MRP2).55, 56 Based on published
reports by Hsiang37 and Chen45 et al, it is believed that hepatic transport (influx and efflux) of SV
acid and PV are equally involved.

Any transporter inhibition, due to co-administration of a

CYP3A4 inhibitor (e.g., CSA), should impact transporter mediated shunting of SV acid and PV
similarly.
Studies to quantify the hazard of rhabdomyolysis for different statins (with different
metabolism) with CYP3A4 inhibitor concomitancy have not been conducted. The purpose of this
investigation is to study spontaneous reports of rhabdomyolysis associated with SV and PV to
determine if the CYP3A4 mediated drug interaction results in a selective increase in
rhabdomyolysis reporting rates based on different statin metabolic pathways. Given the
aforementioned physiochemical characteristics of each statin, we hypothesize an increased risk
for SV, but not for PV, with CYP3A4 inhibitor concomitancy.
METHODS
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We conducted a comparative case series of spontaneous reports of rhabdomyolysis
associated with PV and SV to assess interaction with selected CYP3A4 inhibitors. To control for
population exposure to each statin, we used the estimated total number of PV and SV
prescriptions as denominators for each case group.
Case source: This analysis was conducted at the Food and Drug Administration’s (FDA)
Center for Drug Evaluation and Research (CDER).

Cases consisted of domestic (U.S.)

spontaneous adverse event reports of rhabdomyolysis associated with PV and SV.

These

reports were submitted to the FDA by pharmaceutical manufacturers or health care professionals
through the MedWatch program. MedWatch reports are archived in CDER’s Adverse Events
Reporting System (AERS) database and coded according to the Medical Dictionary for
Regulatory Activities (MedDRA). A concise review of the history and treatment of adverse drug
event reports at CDER, including epidemiological inference, has been reported seaparately.57
Case definition:
Spontaneous reports of rhabdomyolysis associated with PV and SV were obtained from the
AERS database. We acquired all cases of rhabdomyolysis associated with these two agents
from market launch (November 1991 for PV; January 1992 for SV) through July 2001. The cutoff date of July 2001 was selected to limit the effect of stimulated rhabdomyolysis reporting
following the suspension of cerivastatin marketing in August 2001. Reports were selected using
the MedDRA terms rhabdomyolysis, myopathy, or myalgia with further restriction for
rhabdomyolysis that required hospitalization. After identification of putative cases, all reports were
manually reviewed by the authors (C.R., A.B.).
A case of rhabdomyolysis was defined as a patient with a health care professional (HCP)
diagnosis of rhabdomyolysis or a HCP diagnosis of myositis or myopathy with a creatine
phosphokinase (CPK) > 10,000 IU/L.

Exclusion criteria included non-U.S. reports, non-HCP

reports, duplicate reports, “hearsay” reports, published reports, and cases with a history of: nonstatin-related rhabdomyolysis, myositis, dermatomyositis, renal transplantation, or HIV infection /
treatment. In order to reduce confounding by concomitant statin-fibrate exposure, reports listing
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concurrent use of gemfibrozil (GEM) were excluded from the primary analysis, but were included
in a secondary analysis.
Case exposure definition:
Each report was carefully reviewed for specific mention of recent administration of PV or SV
and a concomitant CYP3A4 inhibitor. We further verified the temporality of the statin without a
CYP3A4 inhibitor or the statin-CYP3A4 inhibitor concomitancy to the event date. We required
both the statin and the CYP3A4 inhibitor to be listed (within 30 days of each other) in either the
concomitant medications section or specific mention of a concomitant (statin-CYP3A4 inhibitor)
therapy in the report narrative. Additionally, we required documentation of the statin-CYP3A4
inhibitor concomitancy to be no more than 30 days prior to the event date or specific mention of
close temporal association between concomitant exposure and the event in the narrative.
The CYP3A4 inhibitors chosen for this investigation were: cyclosporine, clarithromycin,
erythromycin,

diltiazem,

verapamil,

mibefradil,

itraconazole,

ketoconazole,

fluconazole,

nefazodone, and fluvoxamine. Despite our attempt to study CYP3A4 inhibitors known for potent
and selective CYP3A4 inhibition, some of the selected CYP3A4 inhibitors also inhibit other
metabolic and uptake transport pathways.
Population exposure source:
Drug utilization data were acquired for the purpose of estimating total U.S. exposure to PV
and SV with and without a CYP3A4 inhibitor during the study period (denominator data). These
data were acquired from two different sources - IMS HEALTH National Prescription Audit Plus
(NPA Plus) and the NAMCS. NPA Plus data were used to estimate the total number PV and SV
prescriptions dispensed in the United States from November 1991 through July 2001.15 The
concomitant statin-CYP3A4 inhibitor frequency was determined using the National Ambulatory
Medical Care Survey (NAMCS).
NAMCS is a national probability sample survey of office-based physicians conducted by the
National Center for Health Statistics, Centers for Disease Control and Prevention. Statistics
derived from NAMCS are representative of all ambulatory care visits to physicians engaged in
non-federal, office-based health care. Participating physicians agree to systematic sampling and
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review (via chart abstraction) of patient visits during a randomly selected week of the year. For
the sampled visits, the physician provides details of specific patient information including patient
demographics, reason for the visit, up to three medical diagnoses, treatments, and disposition.
New and continued prescriptions are recorded as well as other treatments and recommendations.
Data gathered from this survey are transcribed into standard international classification of
diseases (ICD-9) nomenclature. Concomitancy data for PV and SV with a CYP3A4 inhibitor were
collected from NAMCS during the time period 1993-2001. NAMCS is a practical source to
estimate statin-CYP3A4 concomitancy, although it may not be representative of the overall United
States concomitant frequency distribution.
In order to calculate the number of statin prescriptions with a concomitant CYP3A4 inhibitor,
we multiplied the total number of PV and SV prescriptions by the concomitant frequency
proportion for PV and SV with a CYP3A4 inhibitor. The remainder of each calculation is the total
number of PV and SV prescriptions without a CYP3A4 inhibitor.
Measures of effect:
The adverse event reporting rate (AER), measured as number of cases per 10 million
prescriptions, will be calculated using the actual number of cases of rhabdomyolysis associated
with either PV or SV (as the numerator) and the estimated population exposure as the
denominator. The adverse event reporting rate ratio (AERR) will also be calculated to reveal the
relative effect for each statin with and without a concomitant CYP3A4 inhibitor.
The primary analysis consisted of calculating the rhabdomyolysis AER and AERR
associated with PV and SV stratified by the presence or absence of a CYP3A4 inhibitor.
Secondary analyses were conducted to evaluate the potential impact of statin dose and to
compare the rhabdomyolysis AER and AERR with statin-GEM concomitancy.
RESULTS
A search of the AERS database MedWatch reports from 1991 through July 2001, recovered
73 and 321 potential cases of rhabdomyolysis associated with PV and SV respectively. Following
hands-on review, 25 and118 reports, for PV and SV respectively, were classified as unique cases
fitting the case definition. Demographic and clinical characteristics of these cases are shown in
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Table 1. The median age for both groups was 66 years. Fifty-five percent and 44% of the reports
were for female patients for PV and SV, respectively. The median dose reported was 20 mg for
PV and 40 mg SV. The median reported time to onset of rhabdomyolysis was eight months for
PV and 5.5 months for SV. A temporal dose increase was reported in zero out of 25 (0%) PV
cases and 22 out of 118 (19%) SV cases. A switch from one statin to another statin within 60
days of the event was reported in one out of 25 (4%) PV cases and 11 out of 118 (9%) SV cases.
Five (20%) PV and 25 (21%) SV treated patients reported acute renal failure or required dialysis.
Four patients reportedly died from events presumably related to the adverse drug reaction (two
(8%) patients treated with PV and two (2%) treated with SV).
Among the 25 PV and 118 SV associated cases, three (12%) and 56 (47%) reported a
concomitant CYP3A4 inhibitor, respectively. The distribution of PV and SV cases with specific
concomitant CYP3A4 inhibitor is shown in Table 2. Of interest, six cases associated with SV and
one case associated with PV reported two concomitant CYP3A4 inhibitors.
Table 3 shows the SV dose analysis stratified by the presence or absence of a concomitant
CYP3A4 inhibitor. Importantly, the median SV dose with and without a concomitant CYP3A4
inhibitor was equivalent (40 mg). However, the mean SV dose was higher (56 mg vs. 38mg) for
cases reporting a concomitant CYP3A4 inhibitor than for cases not reporting a concomitant
CYP3A4 inhibitor. A similar dose analysis for PV cases was not possible due to missing dose
information among the three PV cases reporting a concomitant CYP3A4 inhibitor. A recent dose
increase was reported was reported in 0 out of 25 (0%) PV cases and 23 out of 118 (19%) SV
cases.
Reporting rate analysis: The NPA Plus audit produced 83,673,000 and 120,188,000 U.S.
dispensed retail prescriptions for PV and SV from initial marketing.15 The observed range of
physician response for NAMCS was 63% (1999) to 73% (1993). Table 4 shows the NAMCS
concomitant frequency data for selected CYP3A4 inhibitors and GEM. The proportion of mentions
of PV and SV with a concomitant CYP3A4 inhibitor was 0.15 and 0.12 respectively. For use in
the secondary analysis, the proportion of concomitant mentions of PV and SV with concomitant
GEM was 0.0079 and 0.0149 respectively. Based on these data, we found the estimated US
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population exposure for PV and SV to be approximately 83 million and 118.4 million U.S.
dispensed prescriptions (without GEM concomitancy). The primary analysis will use these two
numbers for calculating the AER and AERR.
Table 5a shows the unadjusted AER analysis for PV and SV.

Twenty five cases of

rhabdomyolysis associated with PV were identified among an estimated 83 million PV
prescriptions yielding an AER of 3.0 cases per 10 million prescriptions. One hundred eighteen
cases of rhabdomyolysis associated with SV among an estimated 118.4 million SV prescriptions
yielding an AER of 10.0 cases per 10 million prescriptions. Without adjusting for CYP3A4 inhibitor
concomitancy, the rhabdomyolysis AERR (SV/PV) was 3.3.
AERs and AERRs stratified by concomitant use of CYP3A4 inhibitors are shown in Table 5b.
The AERs for PV with and without a concomitant CYP3A4 inhibitor are 2.4 and 3.1 cases per 10
million prescriptions (AERR = 0.77). The AERs for SV with and without a concomitant CYP3A4
inhibitor are 38.4 and 6.0 cases per 10 million prescriptions (AERR = 6.43). Table 5b also shows
the relative effect of SV cases to PV cases. When stratified by CYP3A4 inhibitor, the relative
effect (AERR) of SV/PV was 16.0 (38.4/2.4) with a concomitant CYP3A4 inhibitor and 1.9
(6.0/3.1) without a concomitant CYP3A4 inhibitor.
Tables 6a and 6b show the secondary analysis with concomitant statin and GEM. Twenty
eight PV and 159 SV spontaneous reports of rhabdomyolysis met the prespecified inclusion
criteria. Among these cases, 3 PV and 41 SV cases reported concomitant exposure to GEM. The
crude AERs were 3.3 and 13.2 per 10 million prescriptions for PV and SV, respectively.
Stratifying the PV cases by concomitant GEM gave AERs of 3 and 45 per 10 million prescriptions
with and without GEM, respectively (AERR = 15). Stratifying the SV cases by concomitant GEM
gave AERs of 229 and 10 cases per 10 million prescriptions with and without GEM, respectively
(AERR = 23).
All results use the aggregate proportion of all CYP3A4 inhibitors with a concomitant statin
(SV =0.1526, PV=0.1231). However, individual CYP3A4 inhibitor concomitancy with SV resulted
in AER point estimates greater than the baseline AER (6.0 cases per 10 million SV Rxs without a
CYP3A4 inhibitor) (data not shown).
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DISCUSSION
This descriptive analysis of rhabdomyolysis AERs and AERRs associated with PV and SV
reveals noteworthy effect modification by CYP3A4 inhibitor concomitancy for SV but not PV
(Table 5b). The crude AERs and AERRs (Table 5a) for SV and PV are consistent with previous
findings. Chang et al. reported a crude reporting rate ratio of 4 (SV/PV), which approximates our
curde AERR of 3.3 (SV/PV).15 Contrasting the crude AERR with the stratified AERR (by CYP3A4
inhibitor

concomitancy)

suggests

a

striking

interaction

consistent

with

the

different

pharmacokinetic clearance pathways for PV and SV.
In order to further explore the phase I interaction hypothesis, we conducted a secondary
analysis among PV and SV reports with concomitant GEM as the interacting drug. GEM has been
shown to inhibit Phase I metabolism (via primarily the CYP2C8 isoenzyme), Phase II metabolism
(glucuronidation), and uptake transport (via OATP).46 In contrast to CYP3A4 inhibitors, GEM
minimally inhibits the phase I metabolic pathway for either PV or SV. Thus, we hypothesized no
effect modification for PV and SV with concomitant GEM. Supporting this hypothesis, the results
show that although PV-GEM and SV-GEM concomitancy is associated with elevated AERs
(Table 6b), the relative effect (AERR) is seemingly non-differential between PV (AERR = 15) and
SV (AERR = 23) with versus without GEM.
The statin-GEM findings provide another level of evidence to support the effect modification
found in the primary analysis.

While GEM exhibited interaction potential with cerivastatin

plausibly through both metabolic (CYP2C8) and uptake transport (OATP) pathways, it does not
possess PK characteristics that make it likely to differentially interact with PV or SV. Although
both PV and SV rely on hepatic uptake transport via OATP, neither drug undergoes phase I
metabolism by CYP2C8. Thus, the non-differential finding with concomitant GEM is expected and
reassuring.
As shown in Table 3, stratification by statin dose provides inconclusive results for SV and PV
associated rhabdomyolysis when adjusted for a concomitant CYP3A4 inhibitor. Despite skewed
data with large variances, SV-associated cases have the same median dose regardless of
CYP3A4 concomitancy. However, for PV cases, it is not possible to compare the impact of
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increasing dose between the two strata due to missing dose information for cases reporting
CYP3A4 concomitancy. Further analyses need to be conducted to fully evaluate the potential
interaction by statin dose given missing and inconsistent data inherent to voluntary, spontaneous
reports.
Although the findings from this study are consistent with a robust and selective interaction
between SV and CYP3A4 inhibitors, the study has limitations which should be highlighted.
Spontaneous AERs are believed to underestimate actual incidence rates substantially.

This

occurs because the adverse event must be: diagnosed, attributed to a drug, reported to the FDA
or to the manufacturer, and documented with specific information in order to meet study inclusion
criteria. Furthermore, the discrepancy between reporting rates and incidence rates may increase
as physicians become more comfortable identifying and managing statin-related adverse drug
reactions.
Other limitations involve the quality of case reports. Although the MedWatch form has
changed little during the study period, the content of each case report may differ considerably
from report to report. This difference is further complicated by the reporting source, e.g.,
pharmaceutical manufacturer or health care provider. In order to improve study precision, we
excluded cases reported by non-health care providers and recorded the reporting source as a
potential confounding variable. Fortunately, there was near perfect balance of reports reported to
the FDA by the pharmaceutical manufacturers for SV and PV. However, this does not rule out
differential protocols for managing adverse event reporting between the manufacturers.
Further limitations should be considered regarding the drug utilization estimates (the
denominator used in calculating the adverse event reporting rates (AER)). This is particularly true
for the proportion of concomitant CYP3A4 inhibitor therapy with PV (0.15) and SV (0.12). These
concomitant frequency proportions were derived from NAMCS, a weighted and projected annual
national survey of approximately 2,000 office-based physicians in the US. There may be
substantial variability for infrequent events - such as infrequently used drug products.

This

variability is therefore increased in the assessment of coincident events, such as the concomitant
use of two specific agents (e.g., a rarely used drug product in conjunction with a statin).
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Furthermore, NAMCS may not capture drugs prescribed by non-NAMCS participating
physicians, particularly specialists. Section 9 of the NAMCS survey requests information on
“medications that were ordered, supplied, administered or continued during this visit.” As this
statement is subject to interpretation, one practice may record all patients medications while
another may record only those ordered, supplied, administered or continued during that specific
office visit. For example, if a NAMCS participating primary care physician records the statin
therapy he initiated (or refilled), but does not record the antifungal therapy prescribed by a
dermatologist, the concomitancy therapy is not recorded.
underestimate

the

true

proportion

of

concomitant

This potential inconsistency may
statin-CYP3A4

inhibitor

therapy.

Underestimating concomitancy (statin-CYP3A4 inhibitor or statin-GEM concomitancy) would
overestimate the reporting rates and reporting rate ratios. To better understand the impact of a
potential underestimation of the proportion of statin-CYP3A4 inhibitor concomitancy, we
conducted a sensitivity analysis for different proportions of statin-CYP3A4 inhibitor concomitancy.
Table 7 shows an inverse relationship between the concomitant frequency proportion and the
AERs and AERRs. That is, if the concomitancy estimate is underestimated, the reporting rates
and reporting rate ratios may be biased.
Conclusion
Despite these limitations, our findings are consistent with increased risk of rhabdomyolysis
during concomitant use of SV, a CYP3A4 substrate statin, and a CYP3A4 inhibitor. Additionally,
the results support observations regarding muscle toxicity in SV clinical trials with concomitant
CYP3A4 inhibitors. Further analytic research is warranted to fully elucidate these findings.
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TABLES
AERS TABLE 1

Table 1. Demographic and clinical attributes of domestic spontaneous
reports of rhabdomyolysis associated with pravastatin and simvastatin*
Case attributes
Age (years)
range
median
mean
Sex
female
male
unknown
Weight (lbs)
mean
median
Reported statin switch
number switched (%)
Concomitant meds
median number
standard deviation
Reaction onset (months)
range
median
mean
Outcome variables
hospitalized
death
CK median
CK range
acute renal failure or dialysis
Report characteristics
manufacturer report
report year (median)
report year range

Pravastatin (n=25)
n=16
24 - 79
66
61
n=22
12
10
3
n=5
171
181
n=25
1
n=14
5
3
n=15
0.2 - 33
8
12
n=25
25
2
12,300
1,076 - 700,000
5
n=25
17
1997
1992-2001

* Excluding cases with concomitant gemfibrozil and gemfibrozil prescriptions
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Simvastatin (n=118)
n=102
27-93
66
64
n=110
48
62
8
n=48
181
173
n=118
11
n=106
4
3
n=82
0.1 - 90
5.5
13
n=118
118
2
19,240
761 - 625,333
25
n=118
81
1999
1993-2001

AERS TABLE 2
Table 2. Domestic spontaneous reports of rhabdomyolysis
associated with simvastatin or pravastatin and concomitant
CYP3A4 inhibitors
Number of
Number of
CYP3A4 inhibitor(s)
simvastatin
pravastatin
cases
cases
Statin plus 1 reported inhibitor
clarithromycin

10

mibefradil

10

verapamil

8

nefazodone

6

cyclosporine

5

diltiazem

5

itraconazole

3

erythromycin

2

ketoconazole

1

2

Statin plus 2 reported inhibitors
cyclosporine, diltiazem

1

cyclosporine, itraconazole

1

cyclosporine, ketoconazole

1

cyclosporine, mibefradil

1

cyclosporine, verapamil

1

mibefradil, verapamil

1

Total

1

56

3
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AERS TABLE 3
Table 3. Dose analysis for domestic spontaneous reports of rhabdomyolysis associated with pravastatin and
simvastatin stratified by concomitant use of a selected CYP3A4 inhibitor

Reports of rhabdomyolysis
Number reporting dose (%)
Dose range (mg)
Mean / median / sd (mg)
Reported taking max* statin dose (
Recent statin dose increase (%)

All cases
SV
PV
n=118
n=25
95 (80)
13 (52)
5-160
20-40
47 / 40 / 31
26 / 20 / 10
32 (34)
4 (31)
23 (19)
0 (0)

w/ CYP3A4 inhibitor
SV
PV
n=56
n=3
46 (82)
0
5-160
n/a
56 / 40 / 34 n/a
20 (43)
n/a
13 (23)
n/a

* Max dose refers to the maximum FDA approved dose in the United States (pravastatin = 40mg; simvastatin = 80mg)
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w/o CYP3A4 inhibitor
SV
PV
n=62
n=22
49 (79)
13 (52)
5-80
20-40
38 / 40 / 27
26 / 20 / 10
12 (24)
4 (31)
10 (16)
0 (0)

AERS Table 4
Table 4. Proportion of concomitant mentions of pravastatin or
simvastatin and selected CYP3A4 inhibitors or gemfibrozil in the
National Ambulatory Care Survey (NAMCS), 1993-2001
Selected CYP3A4 inhibitors

Pravastatin

Simvastatin

clarithromycin

0.80%

0.01%

erythromycin

0.77%

0.19%

cyclosporine

0.52%

0.04%

mibefradil

0.06%

0.01%

verapamil

5.02%

3.80%

diltiazem

8.01%

7.53%

nefazodone

0.20%

0.27%

itraconazole/ketoconazole

0.28%

0.39%

15.26%

12.31%

0.79%

1.49%

Combined total
Fibrates
gemfibrozil
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AERS TABLE 5A
Table 5a. Reporting rates (AER) and ratios (AERR) for domestic spontaneous
reports of rhabdomyolysis associated with pravastatin and simvastatin*

Pravastatin

Simvastatin

AERR

All cases
Cases of Rhabdomyolysis
Rxs (1991-2001)
AER (per 107 Rxs)

25
83,012,000
3.0

118
118,397,000
10.0

3.3

* Excluding cases w ith concomitant gemfibrozil and gemfibrozil prescriptions

AERS TABLE 5B

Table 5b. Reporting rates (AER) and ratios (AERR) for domestic spontaneous
reports of rhabdomyolysis associated with pravastatin and simvastatin stratified
by concomitant use of a selected CYP3A4 inhibitor*
w/ CYP3A4
inhibitor

w/o CYP3A4
inhibitor

AERR

Pravastatin cases
Cases of Rhabdomyolysis
Rxs (1991-2001)
AER (per 107 Rxs)

3
12,668,000
2.4

22
70,344,000
3.1

56
14,575,000
38.4

62
103,822,000
6.0

0.77

Simvastatin cases
Cases of Rhabdomyolysis
Rxs (1991-2001)
7

AER (per 10 Rxs)

* Excluding cases w ith concomitant gemfibrozil and gemfibrozil prescriptions
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6.43

AERS TABLE 6A
Table 6a. Reporting rates (AER) and ratios (AERR) for domestic spontaneous
reports of rhabdomyolysis associated with pravastatin and simvastatin**

Pravastatin

Simvastatin

AERR

28
83,673,000
3.3

159
120,188,000
13.2

4

All cases
Cases of Rhabdomyolysis
Rxs (1991-2001)
AER (per 107 Rxs)

** Including cases w ith concomitant gemfibrozil and gemfibrozil prescriptions

AERS TABLE 6B

Table 6b. Reporting rates (AER) and ratios (AERR) for domestic spontaneous
reports of rhabdomyolysis associated with pravastatin and simvastatin stratified
by concomitant use of gemfibrozil**

w/ gemfibrozil

w/o gemfibrozil

AERR

3
661,000
45.4

25
83,012,000
3.0

15

41
1,791,000
228.9

118
118,397,000
10.0
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Pravastatin cases
Cases of Rhabdomyolysis
Rxs (1991-2001)
AER (per 107 Rxs)

Simvastatin cases
Cases of Rhabdomyolysis
Rxs (1991-2001)
AER (per 107 Rxs)

** Including cases w ith concomitant gemfibrozil and gemfibrozil prescriptions
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AERS TABLE 7
Table 7. Sensitivity analysis of statin-CYP3A4 inhibitor concomitancy***
Number of prescriptions
w/ CYP3A4
inhibitor

w/o CYP3A4
inhibitor

Concomitant
%

Pravastatin

AER*

AERR**

w/ CYP3A4
inhibitor

w/o CYP3A4
inhibitor

(n=3)

(n=22)

0

83,012,000

0%

-

2.7

-

4,150,600

78,861,400

5%

7.2

2.8

2.6

8,301,200

74,710,800

10%

3.6

2.9

1.2

12,667,631

70,344,369

15.26%

2.4

3.1

0.8

16,602,400

66,409,600

20%

1.8

3.3

0.5

20,753,000

62,259,000

25%

1.4

3.5

0.4

(n=56)

(n=62)

Simvastatin
0

118,397,000

0%

-

5.2

-

5,919,850

112,477,150

5%

94.6

5.5

17.2

11,839,700

106,557,300

10%

47.3

5.8

8.1

14,574,671

103,822,329

12.31%

38.4

6.0

6.4

17,759,550

100,637,450

15%

31.5

6.2

5.1

23,679,400

94,717,600

20%

23.6

6.5

3.6

29,599,250

88,797,750

25%

18.9

7.0

2.7

* AER is the number of reports/ the number of estimated prescriptions (per 10 million prescriptions)
** AERR is calculated as the reporting rate w / a CYP3A4 inhibitor/ the reporting rate w /o a CYP3A4
*** excluding cases w ith concomitant gemfibrozil and gemfibrozil prescriptions
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ABSTRACT
Purpose: The propensity score was developed to control for differences in observed covariates
for two treatment groups. In drug-drug interaction studies, there are usually more than two nonordered exposure categories. The theoretical framework for the multinomial score was previously
described. However, simulation studies to evaluate the performance characteristics of different
propensity score methods in analyzing multiple, non-ordered exposure categories have not been
published. This is important for empiric investigations where the presence and quantity of model
misspecification is rarely known.
Methods: In a simulated drug-drug interaction study, we evaluated the statistical performance of
multiple multinomial and binary propensity score approaches of confounding adjustment. Monte
Carlo simulations were performed on a synthetic cohort with a binary outcome (Y), three binary
exposure variables (A1, A2, A3=A1*A2), and three covariates (X1, X2, X3). We compared percent
bias, coverage probability, and precision (MSE) of the interaction ratio parameter from four
different binary propensity score adjusted models and the multinomial propensity score adjusted
model. We also compared the relative performance of each propensity score approach to an
unadjusted model (the null model) and the correctly specified multivariate model (the MV model).
We evaluated statistical performance under a variety of scenarios typical of drug safety research.
To achieve this, we determined baseline coefficient values for each parameter from those found
in drug safety research. Holding baseline parameters constant, we varied individual parameters
one at a time to assess performance characteristics under a variety of scenarios. We varied the
sample size, the prevalence of exposure, the strength of association between exposure variables,
the interaction between one exposure variable and a covariate, the outcome incidence, the
strength of the interaction ratio, and propensity score form.
Results: The results from these drug interaction simulations show the multinomial propensity
score adjusted model was the least biased, had the greatest coverage probability, and best
precision compared to four different binary propensity score adjusted models. For all scenarios,
the multinomial propensity score model demonstrated consistently superior statistical
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performance - similar to the rarely identifiable MV model. The multinomial propensity score was
the least biased in the presence of model misspecification.
Conclusion: Investigators conducting drug-drug interaction research should consider using the
multinomial propensity score approach to adjust for confounding.
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INTRODUCTION
Inferring the causal effect of one or more treatments that are not randomly assigned is often
the goal of empiric observational research. However, absent random treatment assignment, the
researcher has no assurance that patients receiving different treatments have similar distributions
of factors that influence outcome occurrence. Therefore, researchers must make every effort to
account for inter-patient differences in pre-treatment (baseline) characteristics, using appropriate
statistical methodology.
One approach to account for (or balance) patient baseline characteristics is to use the
propensity score, which is the predicted probability of treatment conditional on the observed
(baseline) covariates.58 The propensity score is a one dimensional covariate used to describe a
multidimensional covariate matrix, and has been shown to be particularly useful when studying
rare outcomes with many potential confounders, where it is not feasible to include all of the
confounders in the statistical models.59 The propensity score was originally developed to control
for differences in observed covariates for two treatment groups (i.e., for a binary exposure).58
Methods have been described for deriving and using the propensity score for ordered
exposure categories (e.g., in dose response analyses).60-62 However, little research has been
conducted using the propensity score to balance the predicted probability of treatment for more
than two, non-ordered treatment categories.

Imai et. al and Imbens et. al described the

theoretical framework for the multinomial propensity score (PSm).61, 63 They showed the predicted
probability of more than two treatments could be derived given observed covariates. Huang and
colleagues applied the PSm in a cross-sectional study of patient satisfaction with asthma care
(the outcome) associated with twenty different physician groups (the multinomial exposure).64
They showed the multinomial propensity score approach balanced the covariates among the
different physician groups. While this study showed covariate balancing properties of the PSm,
the authors didn't conduct simulations to investigate further PSm performance characteristics
compared to other binary PS approaches or with correlated exposures.
The multinomial propensity score approach has potential applications in numerous settings
where the exposure has more than two categories. A drug-drug interaction (DDI) study is one

27

example of a multinomial exposure. DDI studies often have more than two unordered exposure
categories made up of combinations of an object drug and a precipitant drug. An object drug is a
drug that is affected by a drug-drug interaction (e.g., reduced metabolism and increased
bioavailability). The object drug is often a substrate for a specific hepatic enzyme. A precipitant
drug is a drug that catalyzes the drug-drug interaction through inhibition of the specific hepatic
enzyme. Each patient may be in one of four exposure categories. The exposure categories
include: (i) the object drug only, (ii) the comparator object drug only, (iii) the object drug and the
precipitant drug, and (iv) the comparator object drug and the precipitant drug. Importantly, there
is no assumed ordering to these four exposure categories.

Using this type of DDI study

framework, we propose to evaluate the statistical performance of different propensity score
methods (multinomial and binary) through simulation.
No applied methodologic research using simulations to evaluate different propensity score
methods in multiple, non-ordered exposure categories have been published.

This study

evaluates relative bias, coverage probability, and mean squared error associated with different
binary and multinomial propensity score methods. We simulated scenarios relevant to drug safety
investigations.

By evaluating each propensity score method under different scenarios, we

provide drug-drug interaction researchers with a broadly applicable tool that will guide their choice
of confounding adjustment method. The results from this study provide guidance regarding the
validity of the multinomial propensity score.

If the multinomial propensity score adequately

reduced bias under the scenarios evaluated, we will use this method for confounding adjustment
in the confirmatory drug-drug interaction cohort study.
METHODS
For the simulated drug-drug interaction study, the primary effect estimate is the interaction
between the object drug and the precipitant drug. The interaction term is referred to as the
interaction ratio (I*R). The I*R is a ratio of two ratios. Under the proposed DDI study, the I*R
compares the association of the object drug with the precipitant drug to the association of the
comparator object drug with the precipitant drug, adjusted for the effect of the object drug and
comparator object drug without the precipitant drug. This contrast represents the relative effect of
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the object drug with a concomitant precipitant drug compared to the comparator object drug with
a concomitant precipitant drug independent of the individual effects of either the object drug or
the comparator object drug alone.

Since we are interested in the effect of the drug-drug

interaction independent of the effects of the object/comparator object drugs alone, this
investigation will focus on the I*R.
Simulation approach to creating synthetic cohorts:
We used 1,000 simulated data sets to evaluate the performance of multinomial and binary
propensity score methods. We used Stata version 11.1 to perform all Monte Carlo simulations.
We used the random number generator provided by Stata. The methods for generating normal
(Gaussian) and uniform random numbers in Stata were derived by Knuth (1998) 65; Marsaglia,
MacLaren, and Bray (1964); and Walker (1977).
Monte Carlo simulations were performed on the synthetic cohort of patients with a binary
outcome (Y), three binary primary exposure variables (A1, A2, A3=A1*A2), and three covariates
(X1, X2, X3).

The binary outcome variable (Y), represents the presence or absence of the

outcome (Y=1: outcome present; Y=0: outcome absent). The binary exposure variable A1
represents exposure to either the object drug (A1=1) or the comparator object drug (A1=0). The
binary exposure variable A2 represents exposure to the precipitant drug (precipitant drug present
or absent: A2=1 or A2=0). The binary exposure interaction variable (A3) represents the interaction
between A1 and A2 (A1*A2). When A3=1 cohort members are exposed to the object drug (A1=1)
and the precipitant drug (A2=1). When A3=0 cohort members are exposed to: the object drug
without the precipitant drug (A1=1, A2=0), the comparator object drug with the precipitant drug
(A1=0, A2=1), or the comparator object drug without the precipitant drug (A1=0, A2=0).
To evaluate the multinomial propensity score, we generated a multinomial exposure variable
(A4). This non-ordered, categorical variable was derived from the four possible exposure
categories for A1 and A2. The four categories of A4 are: A4=1 (A1=1,A2=1); A4=2 (A1=1,A2=0);
A4=3 (A1=0,A2=1);

A4=4 (A1=0,A2=0). We generated the covariates X1 and X2 as random

continuous variables (standard normal mean 0; standard deviation 1). We generated X3 as
random binary variable (1,-1) with p(1)=0.0).

To compare to statistical performance of the
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multinomial propensity score, we generated several binary propensity scores from A1, A2, and A3
(described below).
We generated associations among the exposure variables (A1, A2, A3) and covariates (X1,
X2, X3) to approximate those found in medical research. For the exposure variables and
covariates, we varied the coefficients to evaluate statistical performance under a variety of
conditions.
Description of base equations:
In simulation studies the investigator builds equations where associations among the
outcome, exposure, and confounding variables are known (because these associations are
determined by the investigator).

We used three base equations, each with investigator

determined coefficients (see base equations below). Using base equation Y as the true outcome
model, we evaluated how closely each propensity score method estimated the interaction ratio
(λ3) in this model.

Below we present base equations used to derive A1 (the object

drug/comparator object drug), A2 (the precipitant drug present/absent), and Y (the binary outcome
yes/no). In base equation A1 we determined the associations among A1 and the covariates X1,
X2, X3. In base equation A2 we determined the associations among A2 and the exposure variable
A1, the covariates X1, X2, X3, and the A1*X1 interaction. In base equation Y we determined the
association among the outcome variable (Y) and the exposure variables A1, A2, A3 and the
covariates X1, X2, X3.
Base Equation A1 - object/comparator drug model
Logit p(A1=1) = β0 + β1X1 + β2X2 + β3X3
Base Equation A2 - precipitant drug model
Logit p(A2=1) = θ0 + θ1A1 + θ2X1+ θ3X2 + θ4X3 + θ5(A1*X1)
Base Equation Y - true outcome model
Logit p(Y=1) = λ0 + λ1A1 + λ2A2 + λ3A3 + λ4X1+ λ5X2 + λ6X3
Baseline values:
In order to evaluate the performance of each propensity score, we first determined baseline
values for each coefficient in the base equations. Baseline coefficient values were selected
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based on the approximate values in an empiric drug interaction study conducted by the principal
investigator (data not yet published).

Holding baseline values constant, we varied specific

coefficients (one at a time), to evaluate relative bias, coverage probability, and mean squared
error (MSE) under a variety of conditions. The baseline sample size was set to 100,000 synthetic
cohort members.
In base equation A1, the baseline coefficients were set to the following values.
Logit Pr(A1=1) = β0 + β1X1 + β2X2 + β3X3
Baseline coefficients: β0=1.0; β1=1.0; β2=0.0; β3=1.0
The baseline constant (β0) was set to 1.0. This baseline value set the proportion of A1=1 to
0.65 and A1=0 to 0.35. The baseline associations for A1 with X1, X2, and X3 were set to β1=1.0,
β2=0.0, β3=1.0, respectively.
In base equation A2, the baseline coefficients were set to the following values.
Logit Pr(A2=1) = θ0 + θ1A1 + θ2X1+ θ3X2 + θ4X3 + θ5(A1*X1)
Baseline coefficients: θ0=-1.0; θ1=0.2; θ2=0.0; θ3=1.0; θ4=1.0; θ5=0.2
This baseline constant of -1.0 set the proportion of A2=1 to 0.35 and A2=0 to 0.65. The
baseline association between A1 and A2 (θ1) was set to 0.2. This represents a modest association
between the object drug and precipitant drug. The baseline associations for A2 with X1, X2, and
X3 were set to θ2=0.0, θ3=1.0, θ4=1.0, respectively. The baseline interaction between A1 and X1
(θ5) was set to 0.2. This represents a weak interaction between the covariate X1 and the object
drug A1.
In base equation Y, the coefficients were set to the following values.
Logit p(Y=1) = λ0 + λ 1A1 + λ 2A2 + λ 3A3 + λ 4X1+ λ 5X2 + λ 6X3
Baseline coefficients: λ0=-2; λ 1=0.1; λ 2=0.1; λ 3=0.4; λ 4=1.0; λ 5=1.0; λ 6=1.0
The baseline constant of -2.0 (λ0=-2.0) set the proportion of Y=1 to 0.2 and Y=0 to 0.8. The
baseline association between A1 and Y was set to 0.1 (λ1=0.1). The baseline association between
A2 and Y was set to 0.1 (λ2=0.1). The baseline association between A3 and Y was set to 0.2
(λ3=0.4). The baseline association between the covariates (X1, X2, and X3) and the outcome Y
was set to1.0.
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Statistical properties evaluated:
Relative bias was our primary measure of statistical performance. Relative bias reflects the
difference between the estimated λ3 value and the true λ3 value. We expressed relative bias as a
percentage [(estimated λ3 - true λ3)/ true λ3)*100]. Positive (negative) percent bias indicated an
overestimation (underestimation) of the association. Zero percent bias values indicated no bias.
Ninety five percent confidence intervals for percent bias were derived using the bootstrap
percentile method. Based on 1000 simulated λ3 estimates, percent bias was calculated.
We also evaluated coverage probability and mean squared error (MSE) of the estimated
value of λ3. Coverage probability was estimated as the proportion of times the confidence interval
for the estimated value of λ3 included the true value of λ3. Precision was estimated by determining
the MSE value of the estimated value of λ3 over 1000 Monte Carlo repetitions. We determined the
MSE by adding the average bias squared and the average bias standard deviation squared
([average bias]2 + [average bias standard deviation]2).
Propensity score methods to be compared:
We evaluated the performance of the multinomial propensity score and other binary
propensity scores methods in the setting of a hypothetical drug interaction study. Because we are
interesting in studying a four level, non-ordered exposure; the multinomial propensity score was
derived using multinomial logistic regression (MLR).63 MLR is an adaption of binary logistic
regression for multiple, non-ordered outcomes. Using MLR, the multinomial propensity score was
derived by regressing the covariates X1, X2, & X3 on the categorical (four level) exposure variable
A4. MLR compares each exposure category of A4 (1, 2, 3, and 4) through a combination of binary
logistic regressions. As with traditional propensity score methods, MLR is followed by arithmetic
transformation of odds (probability/1-probability) into the predicted probability (odds/1+odds) of
being in one of the following exposure categories: 1 vs 4, 2 vs 4, and 3 vs 4. Category 4 was set
as the base level for MLR. The probability of being in a particular exposure category (1, 2, 3, or 4)
is a quantitative representation of the joint distribution of each exposure category given the set of
covariates. We derived the multinomial propensity score (PS4) by determining the predicted
probability of each A4 category given X1, X2, & X3. Functionally this equates to estimating the
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following conditional probabilities (i) Pr(A4=1| X1, X2, X3), (ii) Pr(A4=2| X1, X2, X3), (i) Pr(A4=3| X1,
X2, & X3), (iii) Pr(A4=4| X1, X2, & X3). Because the cumulative sum of these four probabilities is
one, confounding adjustment with PS4 uses three of the four probabilities.
For comparison with the multinomial propensity score (PS4), we used logistic regression to
derive the predicted probability of other binary exposure variables A1, A2, and A3 given X1, X2, and
X3. Functionally this equates to estimating the following conditional probabilities: Pr(PS1: A1=1|
X1, X2, X3), Pr(PS2: A2=1| X1, X2, X3), and Pr(PS3: A3=1| X1, X2, X3). Below is a summary
derivation of each propensity score evaluated included in this investigation.
PS1:

logit Pr(A1=1) = ρ01 + ρ11X1 + ρ21X2 + ρ31X3

PS2:

logit Pr(A2=1) = ρ02 + ρ12X1 + ρ22X2 + ρ32X3

PS3:

logit Pr(A3=1) = ρ03 + ρ13X1 + ρ23X2 + ρ33X3

PS4:

mlogit Pr(A4=1): ρ041 + ρ141X1 + ρ241X2 + ρ341X3
mlogit Pr(A4=2): ρ042 + ρ142X1 + ρ242X2 + ρ342X3
mlogit Pr(A4=3): ρ043 + ρ143X1 + ρ243X2 + ρ343X3
mlogit Pr(A4=4): ρ044 + ρ144X1 + ρ244X2 + ρ344X3

PS12: PS1 & PS2
We evaluated each of these models in the presence of weak model misspecification.
Evaluating statistical performance in the presence known model misspecification, informs us
about the effectiveness of the different confounding adjustment approaches under this common
(and often unknown) condition. It is often the case in empiric research that model misspecification
occurs. Under model misspecification we did not account for the weak interaction between A1
and X1 (A1*X1). The A1*X1 interaction is depicted in base equation A2.
Propensity score form:
We evaluated each propensity score using three approaches:

spline, categorical, and

continuous covariates. Categorical propensity scores were derived using quintiles of the predicted
probabilities. Spline propensity scores were derived through cubic spline regression with five
interior knot points placed at quintiles of the estimated propensity score. Continuous propensity
scores used the linear form of the predicted probabilities. In general, spline and categorical
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covariates are useful when the relationship between the dependent variable (Y) and the
independent variables is not linear. Regression splines also provide flexibly to model a
nonparametric relationship between the propensity score and outcome variable. We used the
spline propensity score adjustment as the baseline form. While propensity scores stratification
and matching are commonly used methods, applications of these methods with a multinomial
exposure have not been developed.
Outcome models:
All propensity score adjusted outcome models used logistic regression with three exposure
variables (A1, A2, A3) and the propensity score (E[Y| A1, A2, A3, PS]). We refer to propensity score
outcome models using PS* to indicate that we evaluated each propensity score (described
above). We compared each propensity score outcome model to an unadjusted model (the null
model) and a correctly specified multivariable (MV) model. The null model included only exposure
variables regressed on Y (E[Y| A1, A2, A3]). The null model allowed us to quantify bias without
covariate adjustment. The MV model included each exposure variable and the three covariates
regressed on Y (E[Y| A1, A2, A3, X1, X2, X3]). In empiric research, the correctly specified MV
model is rarely known. It is presented in this study to illustrate the relative performance of the
propensity score methods to the performance of the correctly specified model. We present bias,
coverage probability, and MSE for the interaction ratio (the estimated value of λ3) from the null
model, the MV model, and each propensity score model. The five propensity score models were
independently evaluated in PS*. The outcome models are presented below.
Null outcome model: Logit Pr(Y=1) = ξ0 + ξ1A1 + ξ 2A2 + ξ 3A3
MV outcome model: Logit Pr(Y=1) = ω0 + ω 1A1 + ω 2A2 + ω 3A3 + ω 4X1 + ω 5X2 + ω 6X3
PS* outcome model: Logit Pr(Y=1) = φ0 + φ1A1 + φ 2A2 + φ 3A3 + φ 4PS*
Diagnostic evaluation of propensity score balance:
In empiric investigations, with one "real" dataset, researchers commonly evaluate the
distribution of propensity scores for each treatment group. This is done to evaluate balance
between exposed and unexposed individuals given their respective vector of covariates. The
primary reason to check propensity score balance is to evaluate the assumption of positivity.
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Positivity exists when exposed and unexposed individuals exist at every level of each confounder.
While the propensity score does not tell you if there are exposed and unexposed at every level of
each confounder, it provides a composite covariate vector which summarizes the probability of
treatment. Assuming no gross positivity violations, one expects the PS distributions (for exposed
and unexposed) to have some degree of overlap. The proportion of overlap informs the
investigator about the heterogeneity of the composite covariate vector in each treatment group. In
an extreme example, if the distributions of propensity scores, for exposed and unexposed, have
no overlap, an excess in covariate heterogeneity suggests these two groups are not comparable.
In order to evaluate PS balance, we present quintile box plots for each derived propensity
score quintile. Visual inspection of quintile box plots depicts the composite covariate overlap at
each propensity score quintile for each exposure category. For the binary propensity scores
(PS1, PS2, PS3), this equates to evaluating the composite covariate distribution at each
propensity score quintile for exposed and unexposed synthetic cohort members.

For the

multinomial propensity score (PSm), this equates to evaluating the composite covariate
distribution for each propensity score quintile at each of the four exposure categories. Because
PSM is comprised of the predicted probability of four exposure categories (i.e., Pr(A4=1),
Pr(A4=2), Pr(A4=3), and Pr(A4=4)), we present quintile box plots for each exposure category.
Scenarios evaluated (seven simulation studies):
To evaluate the statistical performance of different propensity score methods, we varied
seven different parameters - holding the other baseline values constant. The parameters we
varied are described below.
Confounding:

We evaluated statistical performance over a spectrum of confounding by

changing the associations between the covariates (X1, X2, and X3) and the outcome (Y). In the
true outcome model (base equation Y), we evaluated beta coefficients at 0.0, 0.4, 0.7, 1.0, and
1.39. These values range from no confounding to very strong confounding. For all confounding
strengths, the associations among the exposure variables (A1 and A2) and the covariates (X1, X2,
and X3) were fixed at the baseline values.
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Sample size: We evaluated three sample sizes of 50,000, 100,000, and 150,000 synthetic
cohort members. These sample sizes were chosen to emulate typical drug safety data, to avoid
finite sample bias, as well as to permit the study of both common and rare events.
Prevalence of exposure to the precipitant drug: We evaluated three scenarios for the
prevalence of exposure to the precipitant drug (A2=1). By varying the θ0 coefficient (from base
equation A2), we determined the proportion of the synthetic cohort exposed to the precipitant drug
A2 (A2=1). We evaluated the following three proportions: 0.35 (θ0= -1.0), 0.20 (θ0= -2.0), and 0.10
(θ0= -3.0).
Association between object drug and precipitant drug: We varied the association between
the object drug (A1) and the precipitant drug (A2) using θ1 (from base equation A2). This allowed
us to evaluate each propensity score method in the presence of a null (θ1=0), a moderate
(θ1=0.7), and a strong (θ1=1.39) association. This is equivalent to evaluating different proportions
of concomitant exposure to A1 and A2.
Interaction between the object drug and the covariate: We varied the interaction between the
object drug (A1) and the covariate X1 using θ5 from base equation A2. Varying this association
allowed us to understand how each propensity score method performed in the presence of a null
(θ5=0), a moderate (θ5=0.4), or strong (θ5=0.7) model misspecification.
Incidence of the outcome: We varied the proportion of synthetic cohort members having the
outcome (Y=1). This allowed us to understand how each propensity score method performed
under different incidences of the outcome.

We evaluated each method with the outcome

incidence (Y=1) set at 0.2 (λ0= -2.0), 0.1 (λ0= -3.0), and 0.05 (λ0= -4.0). Given the work by
Cepeda et. al. (ref), the incidence of the outcome may be an important characteristic in
determining the performance of each method.
Association between the interaction ratio with the outcome: We varied the strength of
association between the interaction term (λ3) and the outcome (Y). This allowed us to understand
how each propensity score method performed in the presence of a weak (λ3=0.3), a moderate
(λ3=0.6), or a strong (λ3=0.9) association. Depending on the strength of the association between
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the interaction term and the outcome; it is plausible that the performance of each propensity
score method will vary based on this association.
Propensity score form: Using the baseline coefficient values describe above, we evaluated
the performance of each propensity score as a continuous, spline, and categorical covariate.
RESULTS
The results from the seven simulation studies are presented in Figures and Tables 1-7.
Under each scenario evaluated, the multinomial propensity score model (PS4) demonstrated
superior statistical performance compared to the binary propensity score models (PS1, PS2, PS3,
PS12). Statistical performance of the PS4 model was similar to that of the MV model. As
previously mentioned, it is rarely feasible to fit the MV model. Thus, the ability of the PS4 model
to achieve similar performance is important.
Confounding scenarios: Figures 1a, 1b, and Table 1 show the performance of each model
over the spectrum of confounding (no confounding to very strong confounding). The null model is
increasingly biased, with worsening coverage probability, and less precision (increased MSE) as
the strength of confounding increased. The MV model is consistently unbiased, with excellent
coverage probability, and consistent precision over the spectrum of confounding. The binary
propensity score models (PS1, PS2, PS3, and PS12) were increasingly biased, had worsening
coverage probability, and became less precise as the strength of confounding increased. Over
the spectrum of confounding, the PS4 model demonstrated superior statistical performance
compared to the binary propensity score models. The PS4 model had similar percent bias,
coverage probability, and precision to the MV model.
Sample size variation: Figure 2 and Table 2 show the statistical performance for the three
different sample sizes (50,000, 100,000, and 150,000). For all models evaluated, percent bias
was consistent with narrowing 95% confidence intervals as sample size increased. The null
model and propensity scores models PS1, PS2, PS3, and PS12 revealed excess percent bias for
each sample size. The MV and PS4 models remained consistently unbiased for each sample
size. Coverage probability for the MV and PS4 models remained consistently at 0.95. Coverage
probability for the null and PS1, PS2, PS3, and PS12 models reduced as sample size increased.
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The precision (MSE) of the MV and PS4 models was at least twice as precise as the binary
propensity score models. All models show increased precision with larger sample sizes.
Prevalence of exposure to the precipitant drug: Figure 3 and Table 3 show statistical
performance for three different proportions (0.35, 0.2, 0.1) of synthetic cohort members exposed
to the precipitant drug (A2=1). The null and binary propensity score models (PS1, PS2, PS3, and
PS12) show increasing percent bias as the frequency of precipitant drug exposure decreases.
The MV and PS4 models remained consistently unbiased for each proportion of precipitant drug
exposure. Coverage probability increased for binary propensity score models PS1, PS2, and
PS12 and increased as the proportion of precipitant drug exposure decreased.

Coverage

probability for the MV and PS4 models remained consistent across each proportion of precipitant
drug exposure. For all models, precision was reduced as the proportion of precipitant drug
exposure decreases (i.e., MSE was increased as the proportion of precipitant drug exposure
decreased).
Association between the object drug and the precipitant drug: Figure 4 and Table 4 show the
statistical performance for three different associations (null, moderate, strong) between the object
drug (A1) and the precipitant drug (A2). Across each strength of association between the object
drug and precipitant drug, the MV and PS4 models remained unbiased, had approximately 95%
coverage probability, and maintained a consistent level of precision (MSE).

With the

strengthening association between the object drug and precipitant drug, percent bias and
coverage probability for the null and the binary propensity models score trended toward
decreasing bias and increased coverage probability. These models also showed better precision
(reduced MSE) as the object drug and precipitant drug association strengthened.
Interaction between object drug and covariate: Figure 5 and Table 5 show statistical
performance for the null, moderate, and strong interaction between the object drug (A1) and one
of the covariates (X1). The strength of this interaction represents the amount of model
misspecification. Under model misspecification, only the MV model is correctly specified. For
each interaction level, the MV and PS4 models remained similarly unbiased, with near 95%
coverage probability, and maintained a consistent level of precision. The null model showed less

38

bias, better coverage probability, and greater precision with increasing A1*X1 interaction strength.
The binary propensity score models show varied performance across interaction levels, all with
substantial bias and inferior coverage probability.
Incidence of the outcome: Figure 6 and Table 6 show statistical performance under three
incidences of outcome occurrence (Y=1). For each outcome incidence, the MV and PS4 models
remained unbiased, with near 95% coverage probability. The null, PS1, PS2, PS3, and PS4
models remained consistently biased over each outcome incidence. Coverage probability for the
null and binary propensity score models was greater as the incidence of the outcome decreased.
As evidenced by increasing MSE, precision for all models decreased with lower outcome
incidence.
Strength of the interaction ratio: Figure 7 and Table 7 show statistical performance for three
interaction ratio strengths. The MV and PS4 models showed negligible bias, excellent coverage
probabilities, and consistent precision for varied strengths of interaction ratio. Percent bias
decreased for the null and binary propensity score models as the strength of the interaction ratio
increased. For PS2, PS3, and PS12 coverage probability increased as the strength of the
interaction increased. PS1 showed reduced coverage probability with increasing interaction ratio
strength. Precision was increased (i.e., MSE decreased) for the null and binary propensity score
models as the strength of the interaction ratio increased.
Propensity score form: Figure 8 and Table 8 show statistical performance for the continuous,
spline, and categorical propensity score forms. For PS4, the spline form was less biased but had
similarly good coverage probability and precision compared to the continuous and categorical
forms.
Balance diagnostic: The results from propensity score balance diagnostics are presented in
Figures 9, 10, 11, 12a, 12b, 12c, and 12d. For all propensity scores evaluated, the propensity
score quintile box plots show sufficient covariate balance for each propensity score method to
support the assumption of positivity. This represents similar composite covariate distributions for
each level of the propensity score.
Model convergence for each model evaluated was more than 99%.
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DISCUSSION
The results from these drug interaction simulations show the multinomial propensity score
(PS4) was the least biased, had the greatest coverage probability, and best precision compared
to binary propensity score methods. For all scenarios, the multinomial propensity score model
demonstrated consistently superior statistical performance - similar to the rarely identifiable MV
model. The multinomial propensity score was the least biased in the presence of model
misspecification. This is important for empiric investigations where the presence and quantity of
model misspecification is rarely known.

Superior performance of the multinomial propensity

score was expected since each of the conditional probabilities of exposure, four each of the four
exposure categories, given the set of covariates is determined using multinomial logistic
regression. Binary propensity score methods are limited since they do not account for each of
the four exposure categories simultaneously.
This applied simulation project builds on the theoretical approaches to the multinomial
propensity score described by Imai et al. and Imbens et al.61,
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In addition, these results are

concordant with the findings of Huang et al. who showed the multinomial propensity score
improved covariate distribution balance across twenty exposure categories compared to
conventional methods.64 Researchers evaluating multi-level, non-ordered exposure categories,
particularly in the setting of drug-drug interaction studies, should consider confounding
adjustment with the multinomial propensity score.
The simulated cohort in this investigation was nested in a cohort of object drug and
comparator object drug users. We did not consider scenarios where synthetic cohort members
were truly unexposed. However, investigators may extrapolate these results to other scenarios
where the comparator object drug group alone (A1=0, A2=0) represents an unexposed group.
The results of this investigation are generalizable to other studies under similar scenarios as
those investigated in this study. While we attempted to evaluate broadly applicable scenarios
found in drug safety research, there may be other situations where these results will not be
applicable. For example, we studied statistical performance using a spectrum of confounding,
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three incidences of the outcome, three associations between the object drug and the precipitant
drug, three strengths of the covariate-drug interaction (A1*X1), and three associations of the drug
interaction (A1*A2) with the outcome Y. Despite our efforts to study associations commonly found
in drug safety research, additional research is warranted to evaluate scenarios substantially
different from those we studied.
We evaluated three covariates to estimate statistical performance of different propensity
score methods.

As demonstrated by Cepeda et al.
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, the propensity score is most

advantageous, with regard to bias reduction, when the number of covariates is large compared to
the number of outcomes. Using three covariates adequately demonstrated relative statistical
performance; however, future studies of scenarios with additional covariates with more complex
distributions, interactions, and transformations may be beneficial for drug-drug interaction
researchers.
Matching and stratification on the propensity score are commonly used methods to adjust for
confounding. The complexity of the multinomial propensity score does not extrapolate directly to
either matching or stratification. Methods for matching on a four level categorical exposure have
not been developed. This is an area for future research. Likewise, propensity score stratification
does not have a multinomial equivalent. Given the multinomial propensity score approach
includes three propensity scores used in the final model, propensity score stratification would not
provide a single overall estimate.

This strategy may not be applicable to the multinomial

approach.
The results from this investigation presume the assumptions for causal inference are not
violated.

These assumptions include no unmeasured confounding, positivity, and no model

misspecification.66 We make the assumption that, given measured covariates (X1, X2, and X3),
there are no additional covariates that influence the association among the multi-level exposure
and the outcome.

Investigators must make every effort to evaluate all potential covariates

associated with the exposure and the outcome. This is not a testable assumption. Positivity, on
the other hand, is a testable assumption. As previously stated, positivity exists when exposed
and unexposed individuals exist at every level of each covariate. While this is difficult to test for
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continuous covariates, one may evaluate positivity by examining the composite covariate
distribution for exposed and unexposed individuals. If the distributions are similar, it may be
assumed that positivity is achieved.

We evaluated the quintile box plots for all exposure

categories within each propensity score quintile (for each covariate).
Correct model specification (for logistic regression) means the relationship between the
independent variables and the dependent variable is linear on the log scale.67 However, as
previously described, we intentionally created weak model misspecification through the A1*X1
interaction variable. This was done to evaluate propensity score performance with known model
misspecification. In empiric investigations, model misspecification may often exist, yet be
unknown to the researcher. To provide a comprehensive evaluation (with and without model
misspecification), we evaluated performance with a null, moderate, and strong A1*X1 interaction.
Under all scenarios evaluated, with our without model misspecification, the multinomial propensity
score showed superior statistical performance to binary propensity score methods.
Conclusion
The results from these simulation studies show the multinomial propensity score eliminated
most bias, had greater coverage probability, and increased precision than comparator binary
propensity score methods. The results were essentially comparable to the correctly specified MV
model, which is rarely attainable in empiric research. Based on these results, Investigators
studying drug-drug interactions should consider using the multinomial propensity score approach
to adjust for confounding.
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TABLES
METHODS FIGURE 1 PERCENT BIAS (SPECTRUM OF CONFOUNDING)
Percent bias by the spectrum of confounding
(betas for assoc. b/t Y and Xs: 0.0, 0.4, 0.7, 1.0, 1.39)
100
75

Percent Bias

50
25
0
-25
-50
-75
Null

-100

MV

PS1

PS2

PS3

PS12

PS4

METHODS FIGURE 1A COVERAGE PROBABILITY (SPECTRUM OF CONFOUNDING)
Coverage Probability over the spectrum of confounding

Coverage Probability

1.0
0.8

MV
PS4

0.6

PS1
PS2
PS3

0.4

PS12
Null

0.2
0.0
0.0

0.4

0.7

1.0

1.4

Betas coefficients for association between Y & Xs

METHODS TABLE 1 COVERAGE PROBABILITY AND MSE (SPECTRUM OF CONFOUNDING)
Methods Table 1 (coverage probability and MSE)
confounding
0.0
0.4
0.7
1.0
1.4
0.0
0.4
0.7
1.0
1.4

Null

MV

PS1

Coverage probability
0.953
0.953
0.949
0.944
0.945
0.932
0.611
0.960
0.883
0.041
0.948
0.693
0.000
0.958
0.369
Mean squared error (bias)
0.002
0.002
0.002
0.002
0.002
0.002
0.007
0.002
0.003
0.026
0.002
0.006
0.055
0.002
0.012

PS2

PS3

PS12

PS4

0.950
0.822
0.705
0.612
0.607

0.950
0.920
0.853
0.731
0.627

0.950
0.917
0.825
0.621
0.429

0.954
0.945
0.964
0.950
0.950

0.002
0.004
0.006
0.007
0.008

0.002
0.003
0.004
0.006
0.008

0.002
0.003
0.004
0.008
0.013

0.002
0.002
0.002
0.002
0.002
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METHODS FIGURE 2: PERCENT BIAS (SAMPLE SIZE)
Sample size (50,000; 100,000; 150,000)
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METHODS TABLE 2: COVERAGE PROBABILITY AND MSE (SAMPLE SIZE)
Methods Table 2 (coverage probability and MSE)
Sample size
50,000
100,000
150,000

Null

MV

PS1

PS2

PS3

PS12

PS4

0.817
0.693
0.558

0.776
0.612
0.488

0.827
0.731
0.628

0.771
0.621
0.484

0.956
0.950
0.945

0.008
0.006
0.005

0.010
0.007
0.007

0.008
0.006
0.005

0.010
0.008
0.007

0.004
0.002
0.001

Coverage probability

0.246
0.041
0.002

0.955
0.948
0.951

Mean squared error (bias)
50,000
100,000
150,000

0.028
0.026
0.025

0.004
0.002
0.001
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METHODS FIGURE 3: PERCENT BIAS (PROPORTION A2=1)
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( 0.35, 0.20, 0.10)
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METHODS TABLE 3: COVERAGE PROBABILITY AND MSE (PROPORTION A2=1)
Methods Table 3 (coverage probability and MSE)
Proportion A2
Null
MV
PS1
PS2
=1
0.35
0.20
0.10

PS3

PS12

PS4

Coverage probability

0.041
0.001
0.021

0.948
0.961
0.959

0.693
0.682
0.767

0.612
0.624
0.677

0.731
0.671
0.704

0.621
0.583
0.658

0.950
0.963
0.959

0.006
0.008
0.010

0.007
0.010
0.015

0.006
0.009
0.015

0.008
0.011
0.017

0.002
0.003
0.005

Mean squared error (bias)
0.35
0.20
0.10

0.026
0.050
0.068

0.002
0.003
0.005
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METHODS FIGURE 4: PERCENT BIAS (ASSOC. BETWEEN THE OBJECT AND PRECIPITANT
DRUGS)
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METHODS TABLE 4: COVERAGE PROBABILITY AND MSE (ASSOC. BETWEEN THE
OBJECT AND PRECIPITANT DRUGS)
Methods Table 4 (coverage probability and MSE)
A1 & A2
assoc.
null
weak
stong

Null

MV

PS1

PS2

PS3

PS12

PS4

0.705
0.700
0.796

0.655
0.575
0.586

0.725
0.782
0.870

0.594
0.675
0.752

0.955
0.953
0.941

0.006
0.006
0.005

0.007
0.008
0.009

0.006
0.005
0.004

0.008
0.007
0.006

0.002
0.002
0.002

Coverage probability

0.023
0.103
0.411

0.952
0.950
0.945

Mean squared error (bias)
null
weak
stong

0.027
0.020
0.011

0.002
0.002
0.002
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METHODS FIGURE 5: PERCENT BIAS (STRENGTH OF A1*X1 INTERACTION)
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METHODS TABLE 5: COVERAGE PROBABILITY AND MSE (STRENGTH OF A1*X1
INTERACTION)
Methods Table 5 (coverage probability and MSE)
A1 & X1
interaction
null
weak
stong

Null

MV

PS1

PS2

PS3

PS12

PS4

0.577
0.791
0.863

0.745
0.046
0.001

0.933
0.418
0.668

0.874
0.334
0.133

0.942
0.956
0.949

0.008
0.005
0.004

0.005
0.031
0.054

0.002
0.012
0.007

0.004
0.014
0.022

0.002
0.002
0.002

Coverage probability

0.000
0.685
0.745

0.952
0.955
0.945

Mean squared error (bias)
null
weak
stong

0.066
0.006
0.005

0.002
0.002
0.002
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METHODS FIGURE 6: PERCENT BIAS (FREQUENCY OF OUTCOME OCCURRENCE (Y=1))
Frequency of outcome occurrence (Y=1)
(0.20, 0.10, 0.05)
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METHODS TABLE 6: COVERAGE PROBABILITY AND MSE (FREQUENCY OF OUTCOME
OCCURRENCE (Y=1))
Methods Table 6 (coverage probability and MSE)
Outcome
frequency
0.20
0.10
0.05

Null

MV

PS1

PS2

PS3

PS12

PS4

0.693
0.806
0.916

0.612
0.732
0.808

0.731
0.788
0.853

0.621
0.701
0.801

0.950
0.953
0.950

0.006
0.008
0.010

0.007
0.010
0.017

0.006
0.009
0.015

0.008
0.011
0.017

0.002
0.004
0.008

Coverage probability

0.041
0.086
0.474

0.948
0.950
0.953

Mean squared error (bias)
0.20
0.10
0.05

0.026
0.037
0.037

0.002
0.004
0.008
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METHODS FIGURE 7: PERCENT BIAS (STRENGTH OF THE INTERACTION RATIO (I*R))
Strength of the interaction ratio (I*R)
(weak, moderate, strong)
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METHODS TABLE 7: COVERAGE PROBABILITY AND MSE (STRENGTH OF THE
INTERACTION RATIO (I*R))
Methods Table 7 (coverage probability and MSE)
Interaction
Ratio
weak
moderate
strong

Null

MV

PS1

PS2

PS3

PS12

PS4

0.791
0.459
0.136

0.513
0.796
0.929

0.701
0.800
0.869

0.574
0.712
0.822

0.953
0.939
0.923

0.005
0.011
0.020

0.009
0.005
0.002

0.007
0.005
0.004

0.009
0.006
0.005

0.002
0.002
0.003

Coverage probability

0.140
0.002
0.000

0.946
0.954
0.951

Mean squared error (bias)
weak
moderate
strong

0.018
0.045
0.084

0.002
0.002
0.002

49

METHODS FIGURE 8: PERCENT BIAS (COVARIATE FORM)
Propensity score form
(continuous, spline, categorical)
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METHODS TABLE 8: COVERAGE PROBABILITY AND MSE (COVARIATE FORM)
Methods Table 8 (coverage probability and MSE)
Propensity score
Null
MV
form
Coverage probability
continuous
0.041
0.948
spline
categorical

-

-

PS1

PS2

PS3

PS12

PS4

0.942
0.693
0.633

0.877
0.612
0.724

0.683
0.731
0.440

0.267
0.621
0.698

0.918
0.950
0.932

0.002
0.006
0.007

0.003
0.007
0.006

0.007
0.006
0.011

0.017
0.008
0.006

0.003
0.002
0.002

Mean squared error (bias)
continuous
spline
categorical

0.026
-

0.002
-
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METHODS FIGURE 9 (PS1 BALANCE DIAGNOSTIC)
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METHODS FIGURE 10 (PS2 BALANCE DIAGNOSTIC)
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METHODS FIGURE 11 (PS3 BALANCE DIAGNOSTIC)
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METHODS FIGURE 12A (PS4A BALANCE DIAGNOSTIC)

1 2 3 4 5

1 2 3 4 5

1 2 3 4 5

1 2 3 4 5

A4=1

A4=2

A4=3

A4=4

0

.2

Pr(a4==2)
.4

.6

.8

METHODS FIGURE 12B (PS4B BALANCE DIAGNOSTIC)

1 2 3 4 5

1 2 3 4 5

1 2 3 4 5

1 2 3 4 5

A4=1

A4=2

A4=3

A4=4

0

.1

Pr(a4==3)
.2
.3

.4

.5

METHODS FIGURE 12C (PS4C BALANCE DIAGNOSTIC)
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METHODS FIGURE 12D (PS4D BALANCE DIAGNOSTIC)
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PROJECT 3: CLINICAL IMPORTANCE OF THE DRUG INTERACTION BETWEEN STATINS
AND CYP3A4 INHIBITORS - A RETROSPECTIVE COHORT STUDY IN THE HEALTH
IMPROVEMENT NETWORK (THIN)
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Five key points:
1. We studied the relative hazard of muscle toxicity, renal dysfunction, and hepatic dysfunction
associated with statin 3A4 substrates compared to statin non-3A4 substrates with a concomitant
CYP3A4 inhibitor
2. We found no overall difference in muscle toxicity, renal dysfunction, and hepatic dysfunction
associated with statin 3A4 substrates compared to statin non-3A4 substrates with a concomitant
CYP3A4 inhibitor
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3. The stratified dose response analysis showed a non-significant increased hazard of muscle
toxicity for high dose statin 3A4 substrates with a CYP3A4 inhibitor compared to high dose statin
non-3A4 substrates with a CYP3A4 inhibitor
4. The duration of response analysis showed a non-significant increased hazard of muscle
toxicity in the first six months for statin 3A4 substrates with a CYP3A4 inhibitor compared to statin
non-3A4 substrates with a CYP3A4 inhibitor
5. In this large drug interaction study of statins and CYP3A4 inhibitors, the overall results show no
evidence of increased hazard of statin-related adverse events based on statin metabolism
Requests for reprints should be sent to:
crowan@mail.med.upenn.edu
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ABSTRACT
Title: Statins and concomitant CYP3A4 inhibitors show no difference in statin-related adverse
events based on statin metabolism
Background: Although generally safe, statins have the potential for severe adverse reactions.
Objective: To compare the relative hazard of muscle toxicity, renal dysfunction, and hepatic
dysfunction between patients initiating statins metabolized by the CYP3A4 isoenzyme (statin-3A4
substrates (atorvastatin & simvastatin)) to patients initiating statins not metabolized by the
CYP3A4 isoenzyme (statin non-3A4 substrates (fluvastatin, pravastatin, and rosuvastatin)) with
and without CYP3A4 inhibitor concomitancy.
Methods: The Health Improvement Network (THIN) was used to conduct a retrospective cohort
study from 1990-2008. Each cohort included new statin initiators and compared the relative
hazard of statin-related adverse events. The interaction ratio (I*R) was the primary contrast of
interest. The I*R represents the relative effect of each statin type (statin 3A4 substrate vs. statin
non-3A4 substrate) with a CYP3A4 inhibitor, independent of the effect of the statin type without a
CYP3A4 inhibitor. We adjusted for confounding variables using propensity scores.
Results: The median follow-up time per cohort was 1.5 years. There were 7889 muscle toxicity
events among 362,809 patients. The adjusted muscle toxicity I*R was 1.22 (95% CI: 0.90-1.66).
There were 1449 renal dysfunction events among 272,099 patients. The adjusted renal
dysfunction I*R was 0.91 (95% CI: 0.58-1.44). There were 1434 hepatic dysfunction events
among 367,612 patients. The adjusted hepatic dysfunction I*R was 0.78 (95% CI: 0.45-1.31).
Conclusions: Overall, this study found no difference in the relative hazard of muscle toxicity, renal
dysfunction, or hepatic dysfunction for patients prescribed a statin-3A4 substrate versus a statin
non-3A4 substrate with CYP3A4 inhibitor concomitancy.

55

INTRODUCTION
Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are
effective in the treatment of dyslipidemia, and have been shown to reduce the risk of major
coronary outcomes and all cause mortality.1, 2 While statins are well tolerated by the vast majority
of patients, they are associated with infrequent muscle, renal, and hepatic adverse events.3-9
Statin associated muscle and renal toxicity occur on a continuum from minor myalgias and
proteinuria to severe myositis, renal failure, and fatal rhabdomyolysis.10-12

Statin associated

hepatic toxicity is characterized by transaminitis and rarely serious hepatic dysfunction or hepatic
failure.13, 14 Clinical trials, case reports, and observational studies show these adverse events are
associated with all marketed statins.9, 15-17 While the incidence of serious statin adverse events is
low, muscle toxicity is a leading cause of statin discontinuation.18,

19

It has been shown that

statin-related adverse events occur in a potency dependent manner and therefore may be
exacerbated by pharmacokinetic (PK) statin-drug interactions that increase statin system
exposure.8, 15, 20 17, 21 22-25
Statin-drug interactions occur via inhibition of statin metabolic and/or non-metabolic (i.e.,
hepatic transport) pathways. Statin metabolism involves phase I oxidation (mediated by
cytochrome P450 isoenzymes (CYP)) and phase II glucuronidation (mediated by UDP
glucuronosyl transferase (UGT)). The specific hepatic isoenzymes mediating phase I statin
metabolism are CYP3A4 (for atorvastatin and simvastatin), CYP2C8 (for cerivastatin), CPY2C9
(for fluvastatin), and CYP2C19 (rosuvastatin).

41, 42

Pravastatin undergoes negligible metabolism

by CYP isoenzymes. It is primarily metabolized by glucuronidation (phase II). The non-metabolic
statin pathways are mediated by influx and efflux transport proteins.

Inhibition of statin

metabolism (phase I or II) and/or hepatic transport (influx or efflux) results in elevated statin
plasma concentrations and prolonged systemic exposure, which has the potential to increase the
risk for statin-related adverse events.
Not all statins have the same drug interaction potential. The unique physiochemical property
of each statin makes certain statins more likely to interact with concomitant medications. Of
particular importance is the drug interaction between statins and drugs that inhibit the CYP3A4
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metabolic pathway. The CYP3A4 isoenzyme is the most prevalent isoenzyme in the cytochrome
P450 enzyme system.

The CYP3A4 isoenzyme metabolizes more than 50% of marketed

pharmaceuticals.26 Statins that undergo phase I metabolism by the CYP3A4 isoenzyme are
referred to as statin 3A4 substrates (atorvastatin and simvastatin). Statins that do no use the
CYP3A4 isoenzyme metabolic pathway are referred to as statin non-3A4 substrates (pravastatin,
fluvastatin, and rosuvastatin). CYP3A4 inhibitors prevent CYP3A4 isoenzymes from metabolizing
other drugs (e.g., statin 3A4 substrates). As serious statin adverse events are potency and
plasma concentration related, it is recognized that plasma levels of statins 3A4 substrates may
increase with concomitant administration of CYP3A4 inhibitors.27

Due to the documented

increased systemic statin exposure (demonstrated through PK studies) and increased potential
for adverse events, statin 3A4 substrate product labels warn against concomitant administration
of these statins with CYP3A4 inhibitors.

Despite these warnings, statin 3A4 substrates and

CYP3A4 inhibitors are frequently co-prescribed.51 Commonly used CYP3A4 inhibitors include
calcium channel blockers, H2 receptor antagonists, antibiotics, antifungals, antidepressants,
antiretrovirals, and immunosuppresants.28
Studies quantifying the relative hazard of statin adverse events for different statins (with
different metabolism) with CYP3A4 inhibitor concomitancy are limited. The clinical importance of
this drug interaction was described in an preliminary analysis of spontaneous adverse event
reports associated with statin use.22

In this investigation, we compared the adverse event

reporting rate (AER) and ratio (AERR) of rhabdomyolysis reports for simvastatin (a statin 3A4
substrate) and pravastatin (a statin non-3A4 substrate) with versus without a CYP3A4 inhibitor.
This study showed a six fold increase in the AERR for simvastatin (with vs. without a CYP3A4
inhibitor) and no increase for pravastatin (with vs. without a CYP3A4 inhibitor).22 Given the
limitations of spontaneous report analyses, further research was warranted to fully elucidate
these findings.
The purpose of the current investigation was to study the clinical importance of the drug
interaction between statins and CYP3A4 inhibitors in a large retrospective cohort study. Our
specific aim was to determine the relative hazard of muscle toxicity, kidney dysfunction, and
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hepatic dysfunction associated with statin 3A4 substrates compared to statin non-3A4 substrates
with and without CYP3A4 inhibitor concomitancy. Given the physiochemical properties, drug
interaction potential, and prior research, we hypothesized an increased relative hazard for statin
3A4 substrates compared to statin non-3A4 substrates with CYP3A4 inhibitor concomitancy.
METHODS
Study Population
The study population was drawn from The Health Improvement Network (THIN) from 1990
through October 2008. THIN is an anonymized electronic medical record database of primary
care medical records from the United Kingdom (UK). The database consists of contributions from
415 general practices and data from more than three million actively registered patients (as of
mid-year 2007). Record selection was restricted to acceptable medical records, ensuring that
only patients currently or once permanently registered with a general practice were included.68
Statin initiators were eligible for cohort entry if they were eighteen years of age (at statin
initiation) and registered with a general practice for twelve months prior to the first statin drug
code. The twelve month period prior to statin initiation is referred to as the baseline period. The
rationale for requiring a twelve month baseline period prior to statin initiation is to collect baseline
medical, therapy, outcome, and confounder data.
Exclusion criteria were implemented based on information obtained prior to statin initiation.
We excluded patients not continuously registered during the baseline period and those with a
statin drug code prior to or during the baseline period. Cerivastatin initiators were excluded given
the idiosyncratic increased risk for serious adverse events. We excluded patients with an organ
transplant.
Definition of Exposure
As noted, the cohort included subjects exposed to statins. We categorized statin exposure
by the metabolic properties of each statin with and without a concomitant CYP3A4 inhibitor. Statin
3A4 substrates, metabolized by the CYP3A4 isoenzyme, included atorvastatin and simvastatin.
Statin non-3A4 substrates, not metabolized by the CYP3A4 isoenzyme, included fluvastatin,
pravastatin, and rosuvastatin. Statin potency was evaluated as a categorical, time varying
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covariate. Statin potency categorization was based on percent low density lipoprotein cholesterol
(LDL-C) reduction.69
The four exposure categories included: statin 3A4 substrates with and without a concomitant
CYP3A4 inhibitor and statin non-3A4 substrates with and without a concomitant CYP3A4
inhibitor. We identified CYP3A4 inhibitors from the University of Indiana's cytochrome P450
table.28 We included concomitant exposure to the following CYP3A4 inhibitors: clarithromycin,52
erythromycin,70 telithromycin, norfloxacin, diltiazem,25 verapamil,70 mibefradil71, amiodarone,
ketoconazole,72

itraconazole,50

voriconazole,

fluconazole72,

nefazodone,73

fluvoxamine,74

cyclosporine,47 cimetidine, ritonavir, saquinavir, nelfinavir, indinavir, lopinavir, imatinib, and
aprepitant. For use in secondary analyses, a strong inhibitor was defined as one that causes
greater than 5-fold increase in the plasma AUC values or more than 80% decrease in
clearance.28 A moderate inhibitor was defined as one that causes a greater than 2-fold increase
in the plasma AUC values or 50-80% decrease in clearance.28
Follow-up was measured in person-time on a statin, either with or without a concomitant
CYP3A4 inhibitor, beginning after the first day of the first statin drug code and continued with
subsequent statin drug codes. Due to the pharmacology of the drug interaction, we excluded
outcomes occurring on the first day of statin exposure. Follow-up was censored at the first
occurrence of: (i) the end of the statin days supplied (and no subsequent statin drug code), (ii) a
drug code for a different statin (other than the one they initiated), (iii) the outcome in question, or
(iv) the end of the study (October 2008). Each statin-exposed person-day was attributed to one of
four exposure categories: (i) a statin 3A4 substrate with a CYP3A4 inhibitor, (ii) a statin 3A4
substrate without a CYP3A4 inhibitor, (iii) a statin non-3A4 substrate with a CYP3A4 inhibitor, and
(iv) a statin non-3A4 substrate without a CYP3A4 inhibitor.
Definition of Outcome
To be classified as an outcome, the READ code or laboratory elevation must have occurred
during or within thirty days following the end of included follow-up time, consistent with the work
of Graham and colleagues.8 The thirty day period following the end of statin exposure (with no
subsequent statin exposure) accounts for imperfect patient adherence and delayed outcome
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recording. Outcomes were attributed to one of the four exposure categories. If an outcome
occurred more than thirty days following included follow-up time, patient follow-up was censored.
Outcome definitions were derived from recently published research on statin-related adverse
events.

3-7, 75, 76

Each outcome was analyzed independently. We utilized medical diagnoses or

laboratory evidence to identify incident outcomes. Medical diagnoses are recorded in THIN using
READ codes which are analogous to ICD-9 codes. All READ codes and laboratory criteria were
independently reviewed and verified by the study authors to identify muscle toxicity, renal
dysfunction, and hepatic dysfunction (CR, SB, PR, JM, and JF).
Muscle toxicity was defined by a READ code for muscle symptoms (e.g., myalgia, myopathy,
myositis, and muscle pain) or a creatine kinase (CK) elevation greater than five times the upper
limit of normal (>5 X ULN).
Renal dysfunction was defined by a READ code for acute kidney injury, chronic kidney
disease, end stage renal disease, dialysis, or a doubling of serum creatinine (sCr) (elevated to at
least above the sCr upper limit of normal) over the baseline sCr or a single sCr value greater than
twice the ULN (>2X ULN). The baseline sCr measurement was the lowest sCr value occurring
within 365 days before the elevated sCr measurement. A secondary analysis excluded patients
with a READ code for chronic kidney disease.
Hepatic dysfunction was defined as the first READ code for hepatic failure, toxic liver
disease, acute liver necrosis, acute hepatitis, jaundice, or an ALT/AST measurement greater than
five times the upper limit of normal (>5X ULN). We utilized the 5X ULN ALT/AST outcome
threshold, consistent with the Drug-Induced Liver Injury Network criteria.77 Additionally, we
conducted a secondary analysis of severe transaminitis (using the ALT/AST threshold of 10X
ULN).
Outcomes identified by laboratory evidence were considered confirmed. Outcomes identified
by READ codes with no laboratory evidence but with additional outcome evidence from physician
comments in the electronic medical record were also considered confirmed. We conducted
secondary analyses using confirmed outcomes only.
Confounding Variables
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We evaluated potential confounding variables associated with each outcome from previous
research.17, 19, 21, 78 Patient demographics and medical history were collected during or prior to
the twelve month baseline period prior to statin initiation. Laboratory, patient surveillance, and
pharmaceutical therapy data were collected only during the baseline period. Table 1 shows the
specific potential confounding variables we evaluated.
Due to incomplete baseline laboratory data (e.g., cholesterol, CK, sCr, and ALT/AST), only
baseline cholesterol was evaluated as a potential confounder. The other laboratory measures
were used to evaluate the patient surveillance rate. That is, the number of normal (below the
threshold for outcome/exclusion from the specific cohort) measurements during the baseline
period.
Analysis
For each analysis, patients with documented evidence of the outcome prior to statin initiation
were excluded, as were patients with chronic medical conditions related to that outcome. For the
analyses of muscle outcomes, we excluded those with prior codes for that outcome, and also
those who ever had a code for dermatomyositis or myositis specifically attributed to another
disorder. For the analyses of the renal dysfunction outcome, we excluded those with prior codes
for that outcome, patients with a sCr above the upper limit of normal within the twelve months
prior to statin initiation, and also those who ever had codes for genetic kidney disease and
chronic nephritis. For the analyses of the hepatic outcomes, we excluded patients with prior
codes for that outcome, with an ALT or AST greater than 3X ULN within twelve months prior to
statin initiation, and those who ever had a history of alcoholism and viral hepatitis. As noted,
patients with chronic conditions (e.g., dermatomyositis, chronic nephritis, and alcoholism) were
excluded, even if those chronic conditions were first diagnosed after cohort entry; since these
were chronic conditions, we felt their appearance after cohort entry was simply a reflection of
when the disease was recorded in the medical record, rather than the true onset of the condition.
In a planned secondary analysis, we censored follow-up at documentation of these specific
conditions, rather than excluding the entire patient record.
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In descriptive analyses, continuous variables were described using means and categorical
variables were described using percentages.
The primary effect estimates were derived through Cox proportional hazards regression.79
Statin potency was included as a time varying covariate in each analytic model. The contrast of
interest is the interaction ratio (I*R). The I*R is a ratio of two hazard ratios (HR). It represents the
relative hazard of each statin type with a concomitant CYP3A4 inhibitor adjusted for the hazard of
each statin type without a CYP3A4 inhibitor. This method controls for the hazard of the outcome
associated with each statin type alone, thus, focusing on the effect on the differential hazard due
to the statin-CYP3A4 inhibitor interaction.
In addition to the primary analyses, we conducted secondary analyses of those with
confirmed outcomes.

Other secondary analyses evaluated the effect of statin potency and

duration of response.
In order to evaluate different CYP3A4 inhibitor potencies, we conducted secondary analyses
restricted to CYP3A4 inhibitors exhibiting moderate and strong inhibitory characteristics. We also
conducted secondary analyses based on duration of CYP3A4 inhibitor use. We evaluated the I*R
for antibiotics and antifungals as short duration CYP3A4 inhibitors and other long duration use
drugs (e.g., antihypertensives) as chronically used CYP3A4 inhibitors. We also present an
analysis with specific concomitant CYP3A4 inhibitors.
To control for confounding we used the multinomial propensity score. Multinomial propensity
score methodology was described by Imai and Imbens and applied by Huang.61,
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The

multinomial propensity score determines the probability of being in each exposure category given
baseline covariates. Using the propensity score variable selection method described by
Brookhart,80 we included only baseline variables associated (p<0.1) with the outcome.

This

confounder selection procedure was conducted independently for each outcome. To assess
baseline covariate balance we graphically evaluated the distribution of propensity scores for each
of the four exposure categories. Graphic representation of propensity score distributions showed
ample overlap to permit valid comparison among the four exposure categories (data not shown).
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Missing data was handled using median value imputation and multiple imputation. For
statins or CYP3A4 inhibitors missing the prescribed quantity or dosing instructions, we used
median value imputation based on the derived median prescription duration for statins or
CYP3A4 inhibitors with available prescribed quantity and dosing instructions. The proportion of
statin and CYP3A4 inhibitor drug codes missing either the prescribed quantity or dosage
instructions was 0.1 for statins and 0.2 for CYP3A4 inhibitors. Baseline body mass index (BMI)
and cholesterol values were imputed using multiple imputation.81 We determined the average
propensity score adjusted interaction ratio from ten imputed datasets. Rubin's method was used
to determine the variance; this method accounts for the within and between dataset variation.81, 82
Monte Carlo simulation was used to estimate empiric power. Based on an estimated
600,000 and 50,000 statin person-years with and without a concomitant CYP3A4 inhibitor
(respectively), our empiric power simulations determined there was more than 80% power to
detect an I*R of 2.0 (or above), for each outcome.
Stata version 11.1 was used to perform all analyses.
This study was approved by the Institutional Review Board at the University of Pennsylvania
and registered with the National Health Service - Central Office for Research Ethics Committees
(COREC), United Kingdom.
RESULTS
Figure 1 displays the subjects in the cohort who were excluded/included in each analysis.
The median follow-up time in each analysis was 1.5 years (see Table 1). Approximately 88% of
patients initiated a statin 3A4 substrate. Mean age, proportion of males, and BMI were balanced
within between statin 3A4 substrate and statin non-3A4 substrate initiators.
The results for muscle toxicity (primary and confirmed outcome analyses) are presented in
Table 2a.

Baseline variables associated with muscle toxicity and therefore included in the

propensity score adjusted model are listed at the bottom of Table 2a. The adjusted relative
hazard of muscle toxicity for each statin type with a concomitant CYP3A4 inhibitor, adjusted for
the effect of each statin type without a CYP3A4 inhibitor is depicted by the I*R. The primary
muscle toxicity adjusted I*R (95% CI) was 1.22 (0.90-1.66). The confirmed muscle toxicity I*R
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(adjusted) was 0.90 (0.53-1.52). Muscle toxicity hazard ratios for each statin type with versus
without a CYP3A4 inhibitor are presented in Table 2a.
The results for renal dysfunction (primary analysis, confirmed outcome analysis, and CKD
exclusion analyses) are presented in Table 2b. The baseline variables included in the propensity
score adjusted model are listed at the bottom of Table 2b. For the primary renal dysfunction
analysis the adjusted I*R was 0.91 (0.57-1.43). The confirmed renal dysfunction outcome I*R
(adjusted) was 0.86 (0.50-1.45). The adjusted I*R excluding CKD outcomes was 0.91 (0.551.49).

Renal dysfunction hazard ratios for each statin type with versus without a CYP3A4

inhibitor are presented in Table 2b.
The results for hepatic dysfunction (primary, confirmed, and ALT/AST >10X ULN) are
presented in Table 2c. The baseline variables included in the propensity score adjusted model
are listed at the bottom of Table 2c. For the primary analysis the adjusted I*R for renal
dysfunction was 0.78 (0.45-1.33). The confirmed hepatic dysfunction outcome (adjusted) I*R was
0.66 (0.38-1.14). The adjusted I*R for the ALT/AST 10X ULN was 0.85 (0.39-1.87). Hepatic
dysfunction hazard ratios for each statin type with versus without a CYP3A4 inhibitor are
presented in Table 2c.
Statin potency analyses are presented in Table 3. The table shows specific statin dosages
included in each category. The test for trend among the muscle toxicity potency strata was not
significant (p=0.46). For renal dysfunction, due to sparse events (and person-years) in the statin
non-3A4 substrate with a CYP3A4 inhibitor exposure category, we could not obtain an interaction
ratio in the high potency strata.
Duration of response analyses are presented in Table 4. Due to sparse events in the statin
non-3A4 substrate with a CYP3A4 inhibitor exposure category, we could not obtain stable
interaction ratios earlier than six months following statin initiation.

We also attempted to

determine the I*R during the first course of statin therapy, but there were insufficient person-years
and events to obtain stable I*R estimates. Given this, we stratified the duration of follow-up as
follows: 0-6 months, 6-12 months, 12-24 months, and >24 months.
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Table 5 describes the person-years and events for specific CYP3A4 inhibitors jointly
prescribed with statins.

Overall, the concomitant statin-CYP3A4 inhibitor person-years and

events were similarly distributed for patients exposed to statin 3A4 substrates and statin non-3A4
substrates. For each cohort, diltiazem, verapamil, and amiodarone make up nearly 85% of all
CYP3A4 inhibitor concomitancy among statin users.
The results from the secondary analysis censoring follow-up for patients with specific chronic
medical conditions identified after statin initiation rather than excluding the entire patient record
were consistent with the primary findings (data not shown). For each outcome, the I*R from the
moderate/strong CYP3A4 inhibitor analysis and the short/chronic CYP3A4 inhibitor analysis were
consistent from the primary analysis findings (data not shown).
DISCUSSION
For each outcome, the primary and confirmed analyses show no significant increased
hazard associated with statin 3A4 substrates compared to statin non-3A4 substrates with a
concomitant CYP3A4 inhibitor, adjusted for the hazard of each statin type without a concomitant
CYP3A4 inhibitor. The I*R is an appropriate effect estimate for evaluating the clinical importance
of drug interactions provided a suitable comparator group is available. For the primary and
confirmed outcome analyses, statin person-years in each of the four exposure categories
contributed sufficient person-years to allow I*R estimation. The results from this investigation
indicate the clinical implications of this well documented drug interaction may be of less
importance than suggested by pharmacokinetic studies, case reports, and analyses of
spontaneous reports.
Pharmacokinetic studies consistently show rapidly increased systemic statin exposure with
co-administration of statin 3A4 substrates and a CYP3A4 inhibitor compared to statin 3A4
substrates alone.71, 83-85 The results of this study suggest the short term increased systemic statin
exposure does not translate into increased hazard for statin-related adverse events. We
evaluated the early effect this drug interaction by conducting a duration-of-response analysis. For
renal and hepatic dysfunction, the I*R showed no increased hazard in the first six months
following statin initiation. For muscle toxicity, the I*R showed a non-significant increased hazard
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in the first six months following statin initiation (I*R=2.07 (0.95-4.48)). Further evaluation of
muscle toxicity may be warranted within six months following the joint exposure to statins and
CYP3A4 inhibitors.
Previous research shows statin potency is associated with muscle toxicity.19, 21 As expected,
we saw an increase in the hazard of all three outcomes for each successive increase in statin
potency, not quite statistically significant for renal dysfunction (data not shown). However, the
continuous potency analysis shows the association between statin potency and the outcome, but
does not address the differential hazard for each statin type with a CYP3A4 inhibitor, compared to
each statin type without a CYP3A4 inhibitor. This contrast (i.e., the I*R) is depicted in the stratified
potency analyses, where the interaction ratios show no increasing effect in subsequent potency
strata.
Other recent observational studies evaluated statin-associated adverse events with
concomitant CYP3A4 inhibitors. Cziraky and colleagues reported a six fold (RR=6.01 95% CI
(2.08-17.38)) increased risk of muscle toxicity for statins with CYP3A4 inhibitors compared to
atorvastatin alone.9 However, statin exposure was aggregated among all person-years attributed
to cerivastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin with a
concomitant CYP3A4 inhibitor. Stratification of statin exposure by oxidative metabolism was not
evaluated, so they could not disaggregate the independent risk from the CYP3A4 inhibitor from
the risk from the drug interaction. In the present study, the interaction ratio separates the effect of
the statin type with a CYP3A4 inhibitor from the effect of each statin type without a CYP3A4
inhibitor.
The results from the present study are also discordant from our preliminary spontaneous
report study in which we found a six fold increased adverse event reporting rate ratio (AERR) for
simvastatin reports with a concomitant CYP3A4 inhibitor compared to simvastatin reports without
a concomitant CYP3A4 inhibitor.22 Substantial methodologic differences favoring validity in the
present study likely drive the inconsistent finding. The present study included only new statin
initiators, excluded patients with prior outcomes, excluded organ transplant patients, used a
validated electronic medical record database, adjusted for potential confounding variables, had a

66

true denominator of statin person-years with and without CYP3A4 inhibitor concomitancy, was not
dependent on external outcome reporting, and used Cox proportional hazards regression to
estimate the interaction ratio with 95% confidence intervals. Spontaneous report analyses are
critical for signal generation. However, the conclusiveness of their findings is limited.86 The
present study is the largest observational study specifically designed to evaluate the clinical
importance of the statin-CYP3A4 inhibitor drug interaction.
THIN has been used in many epidemiologic studies and has been validated for numerous
medical conditions including studies of statin-related side effects.87-89 Despite this, practice
patterns, patient populations, prescribing patterns, and patient surveillance may be systematically
different in the UK from in other countries. We compared the baseline patient characteristics in
this study to those in other recent statin safety investigations.3-7,

9, 75, 78, 90, 91

These baseline

patient characteristics were consistent with the baseline patient characteristics from other US,
Canadian, and European statin safety cohorts.
Regarding confounding, we did not control for variables which we could not identify or could
not measure. However, we captured important variables previously shown to be risk factors for
each outcome. We also separately controlled for confounding by chronic diseases, whether they
were diagnosed before or after the initiation of the statin; the results were the same.
We addressed potential bias associated with depletion of susceptibles by including only new
statin initiators.

The rationale for employing the new user design is to circumvent under-

ascertainment of outcomes occurring early in therapy and to evaluate potential confounders prior
to statin exposure. This is important because some potential confounders (e.g., cholesterol) may
change as a result of statin exposure. Furthermore, if outcomes occurred rapidly following statin
initiation, as was expected with muscle toxicity and hepatic dysfunction, and if the occurrence of
these early outcomes were associated with statin type, our estimates would be biased. The new
user design diminishes this risk of this potential bias.
In order to minimize exposure misclassification, we defined precise exposure criteria for
each exposure category, used up to date drug codes, and carefully constructed exposure
episodes. Use of THIN diminishes the possibility of poor medication adherence, since in the UK
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patients are given only a 28-day prescription at a time.

Regardless, we would not expect

medication adherence to differ by statin type.
One noteworthy class of CYP3A4 inhibitors not represented in this investigation is
antiretroviral therapy (e.g., ritonavir, saquinavir, nelfinavir, indinavir, and lopinavir).

This

investigation included person-years of concomitant exposure to statins and antiretrovirals, but
there was negligible use included in THIN. In the UK, antiretroviral treatment is given mainly by
specialized genitourinary medical clinics, not by physicians in general practice. The results from
this investigation may or may not extrapolate to statins with concomitant antiretroviral therapy.
Outcome misclassification threatens the validity of all retrospective cohort studies. To
evaluate potential outcome misclassification, we conducted secondary analyses restricted to
confirmed outcomes. This provided a sensitivity analysis to reveal the accuracy of our original
outcome classification; the findings from the confirmed outcome analyses were consistent with
the primary analyses.
Conclusion
This large retrospective cohort study showed no overall increased hazard for muscle toxicity,
renal dysfunction, or hepatic dysfunction associated with statin 3A4 substrates compared to statin
non-3A4 substrates with versus without a concomitant CYP3A4 inhibitor. Additional research
could further evaluate the non-significant yet increased muscle toxicity interaction ratio we
observed for highly potent statin dosages and within six months following statin initiation.
However, it is clear that the drug interaction between statins and CYP3A4 inhibitors does not
represent an important public health concern.
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TABLES
THIN FIGURE 1
Figure 1. Subjects excluded/included in the muscle, renal, hepatic cohorts
Excluded from all cohorts:

Total statin users
(1990-2008)

Prevalent/former statin users

n=487,727

n=106,539 Cerivastatin initiators
Organ transplant patients

Excluded because of outcome evidence prior
to the first statin or other chronic muscle,
renal, or hepatic disorders
n=381,188

n=18,379

Muscle cohort

n=109,089

Renal cohort

n=13,576

Hepatic cohort

Subjects included in
the muscle cohort

Subjects included in
the renal cohort

Subjects included in
the hepatic cohort

n=362,809

n=272, 099

n=367,612
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THIN TABLE 1
Table 1. Subject characteristics - (at or prior to the first statin)
Baseline characteristics

Muscle cohort
Statin 3A4
Statin nonsubstrate
3A4 substrate

Renal cohort
Statin 3A4
Statin nonsubstrate
3A4 substrate

# of statin initiators
325,460
37,349
243,707
Age (mean)
63
64
62
<54
22%
22%
26%
55-64
29%
30%
32%
65-74
30%
32%
28%
>75
20%
17%
14%
Male
54%
54%
56%
BMI (mean)
28
28
28
Alcoholism
1.6%
1.3%
1.9%
Current smoker
11%
6%
12%
Medical diagnoses (anytime prior to statin initiation)
CHF
4%
5%
2%
Previous MI
28%
37%
26%
Previous Stroke
4%
5%
4%
Diabetes
21%
19%
19%
Hypertension
52%
49%
47%
Hypothyroidism
4%
4%
4%
Acute kidney disease
0.5%
0.4%
excluded
Chronic kidney disease
3.4%
1.2%
excluded
Acute liver disease
0.4%
0.3%
0.3%
Chronic liver disease
0.3%
0.2%
0.3%
Subject Surveillance Rate (within 12 months prior to statin initiation)
Office visits
2.0
1.7
1.8
Serum creatinine
1.0
0.6
0.9
ALT or AST
0.7
0.4
0.7
Baseline labs (within12 months prior to statin initiation)
Total cholesterol (mmol/L)
n
273,245
26,734
202,169
% w/measurement
84.0
71.6
83.0
mean cholesterol
6.3
6.4
6.3
Serum creatinine (sCr) (μmol/L)
n
235,183
18,122
166,387
% w/measurement
72.3
48.5
68.3
93.1
95.1
83.9
mean sCr
ALT or AST (U/L)
n
150,614
8,827
109,144
% w/measurement
46.3
23.6
44.8
mean ALT
28.8
29.1
30.1
Creatine Kinase (CK) (U/L)
n
16,090
1,120
11,625
% w/measurement
4.9
3.0
4.8
mean CK
112.1
112.0
126.0
First statin
Atorvastatin
26%
25%
Simvastatin
74%
75%
Fluvastatin
17%
Pravastatin
64%
Rosuvastatin
19%
Standardized statin potency category (at statin initiation)
Low
20%
59%
20%
Medium
49%
23%
49%
High
31%
18%
31%
Pharmacotherapy (at statin initiation)
6%
8%
5%
CYP3A4 inhibitor
Diabetes drug
11%
10%
10%
Hypertension drug
63%
64%
57%
Thyroid drug
7%
7%
6%
Gemfibrozil
0.1%
0.1%
0.1%
Other fibrate
1.1%
1.8%
1.0%
Niacin
0.0%
0.0%
0.0%
Vitamin D
2.0%
1.4%
1.6%

70

Hepatic cohort
Statin 3A4
Statin nonsubstrate
3A4 substrate

28,392
62
27%
32%
29%
13%
56%
28
1.5%
6%

329,668
64
21%
29%
30%
20%
53%
28
excluded
11%

37,944
63
22%
30%
32%
17%
53%
28
excluded
6%

3%
35%
4%
16%
45%
3%
excluded
excluded
0.3%
0.3%

4%
28%
4%
21%
52%
5%
0.5%
3.4%
excluded
excluded

5%
37%
5%
19%
49%
4%
0.4%
1.2%
excluded
excluded

1.6
0.6
0.4

2.0
1.0
0.7

1.7
0.6
0.4

19,707
69.4
6.5

276,993
84.0
6.3

27,150
71.6
6.4

12,124
42.7
84.9

238,169
72.2
93.1

18,395
48.5
95.1

6,195
21.8
30.1

151,670
46.0
27.3

8,887
23.4
27.3

800
2.8
131.2

17,012
5.2
122.8

1,172
3.1
124.3

17%
63%
20%

26%
74%
-

17%
64%
19%

59%
22%
19%

20%
49%
31%

59%
23%
18%

7%
8%
60%
6%
0.2%
1.8%
0.0%
1.1%

6%
11%
63%
7%
0.1%
1%
0.01%
0%

8%
10%
65%
7%
0.1%
2%
0.01%
0%

THIN TABLE 2A
Table 2a. Muscle toxicity analyses: number of events (events), person-years (p-y), incidence rates per 1000 person
years (IR), unadjusted and adjusted hazard ratios (HR), and unadjusted and adjusted interaction ratios (I*R)
Events

p-y

IR

446

50608

8.81

6688

657276

10.18

49

7227

6.78

706

77555

9.10

7889

792665

9.95

131

50608

2.59

2358

657276

3.59

17

7227

2.35

212

77555

2.73

2718

792665

3.43

Unadjusted
Adjusted†
HR (95% CI)

Unadjusted
Adjusted†
I*R (95% CI)

Primary analysis
statin 3A4 substrate‡ + CYP3A4X↑
statin 3A4 substrate*
statin non-3A4 substrate + CYP3A4X
statin non-3A4 substrate
Totals

0.93
(0.85-1.03)

0.97
(0.88-1.07)

0.76
(0.57-1.01)

0.75
(0.56-1.00)

0.79
(0.66-0.94)

0.88
(0.74-1.06)

1.20
(0.89-1.63)

1.22
(0.90-1.66)

0.87
(0.52-1.48)

0.90
(0.53-1.52)

Confirmed outcomes
statin 3A4 substrate + CYP3A4X
statin 3A4 substrate
statin non-3A4 substrate + CYP3A4X
statin non-3A4 substrate
Totals

0.89
(0.54-1.46)

0.94
(0.57-1.55)

†Model adjusted for the following baseline variables (i.e., at or prior to statin initiation): age, sex, cholesterol, year at statin initiation, CHF,
stroke, diabetes, hypothyroidism, fluoroquinolone antibiotics, diabetes drugs, thyroid drugs, number of office visits, sCr measurements,
and ALT/AST measurements during the baseline period, statin potency (as a time varying covariate)
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THIN TABLE 2B
Table 2b. Renal dysfunction analyses: number of events (events), person-years (p-y), incidence rates per 1000
person years (IR), unadjusted and adjusted hazard ratios (HR), and unadjusted and adjusted interaction ratios (I*R)
Events

p-y

IR

†
Unadjusted
Adjusted
HR (95% CI)

†
Unadjusted
Adjusted
I*R (95% CI)

Primary
statin 3A4 substrate + CYP3A4X

175

33543

5.22

1119

478830

2.34

25

4872

5.13

130

57339

2.27

1449

574584

2.52

statin 3A4 substrate + CYP3A4X

131

33543

3.91

statin 3A4 substrate

701

478830

1.46

statin non-3A4 substrate + CYP3A4X

20

4872

4.10

statin non-3A4 substrate

82

57339

1.43

574584

1.63

statin 3A4 substrate
statin non-3A4 substrate + CYP3A4X
statin non-3A4 substrate
Totals

2.10
(1.79-2.46)

1.69
(1.43-1.99)

2.21
(1.44-3.39)

1.80
(1.16-2.79)

2.53
(2.09-3.05)

2.15
(1.77-2.60)

0.95
(0.60-1.50)

0.91
(0.57-1.43)

0.90
(0.51-1.46)

0.86
(0.50-1.45)

0.96
(0.59-1.57)

0.91
(0.55-1.49)

Confirmed outcomes

Totals
934
Excluding chronic kidney disease outcomes
statin 3A4 substrate + CYP3A4X

152

33543

4.53

statin 3A4 substrate

935

478847

1.95

22

4872

4.52

111

57339

1.94

1220

574601

2.12

statin non-3A4 substrate + CYP3A4X
statin non-3A4 substrate
Totals

2.80
(1.71-4.56)

2.23
(1.35-3.69)

2.20
(1.85-2.62)

1.75
(1.46-2.08)

2.27
(1.44-3.60)

1.79
(1.12-2.86)

†Model adjusted for the following baseline variables (i.e., at or prior to statin initiation): age, sex, BMI, cholesterol, alcoholism, year at statin
initiation, CHF, MI, stroke, diabetes, hypertension, vitamin D, diabetes drug use, hypertension drug use, # of office visits during the baseline
period, statin potency (as a time varying covariate)
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THIN TABLE 2C
Table 2c. Hepatic dysfunction analyses: number of events (events), person-years (p-y), incidence rates per 1000 person
years (IR), unadjusted and adjusted hazard ratios (HR), and unadjusted and adjusted interaction ratios (I*R)
Events

p-y

IR

Unadjusted
Adjusted†
HR (95% CI)

Unadjusted
Adjusted†
I*R (95% CI)

Primary analysis
statin 3A4 substrate + CYP3A4X
statin 3A4 substrate
statin non-3A4 substrate + CYP3A4X
statin non-3A4 substrate
Totals

116

52957

2.19

1183

675312

1.75

18

7624

2.36

117

80052

1.46

1434

815945

1.76

97

52957

1.83

1024

675312

1.52

18

7624

2.36

102

80052

1.27

1241

815945

1.52

62

52961

1.17

627

675358

0.93

8

7625

1.05

57

80056

0.71

1.25
(1.03-1.52)

1.19
(0.97-1.44)

1.62
(0.99-2.66)

1.64
(0.98-2.72)

1.21
(0.98-1.50)

1.20
(0.97-1.49)

0.78
(0.46-1.32)

0.78
(0.46-1.33)

0.65
(0.37-1.11)

0.66
(0.38-1.14)

0.86
(0.39-1.88)

0.85
(0.39-1.87)

Confirmed outcomes
statin 3A4 substrate + CYP3A4X
statin 3A4 substrate
statin non-3A4 substrate + CYP3A4X
statin non-3A4 substrate
Totals
ALT/AST 10X ULN OR med codes
statin 3A4 substrate + CYP3A4X
statin 3A4 substrate
statin non-3A4 substrate + CYP3A4X
statin non-3A4 substrate

1.86
(1.12-3.07)

2.01
(1.20-3.36)

1.27
(0.97-1.65)

1.14
(0.87-1.49)

1.47
(0.70-3.09)

1.34
(0.63-2.86)

Totals
754
816000
0.92
†Model adjusted for the following baseline variables (i.e., at or prior to statin initiation): age, sex, cholesterol, year at statin initiation, CHF, MI,
stroke, diabetes, hypertension, hypothyroidism, diabetes drugs, hypertension drugs, # of office visits, sCr measurements, ALT/AST
measurements in the 12 months prior to statin initiation, statin potency (as a time varying covariate)
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THIN TABLE 3
Table 3. Standardized potency† analysis
Outcome

Muscle toxicity

Renal dysfunction

Hepatic dysfunction

Statin

‡

Potency

# of
Events

Personyears

IR/1000 p-y

Adjusted
I*R

low1

1436

166470

8.63

1.06

medium2

3405

348824

9.76

1.28

(0.77-2.11)

high3

3048

277371

10.99

2.85

(0.70-11.62)

low

291

120934

2.41

0.84

(0.39-1.83)

medium

620

251108

2.47

0.78

(0.42-1.45)

†

95% CI
(0.87-1.12)

high

538

202542

2.66

-

-

low

257

171580

1.50

0.51

(0.22-1.15)

medium

high
† Statin potency standardization

609

359195

1.70

1.27

(0.97- 1.67)

568

284086

2.00

0.97

(0.13-7.45)

1

Low potency: < 25% LDL-C reduction (atorvastatin <=5mg, simvastatin <=10mg, fluvastatin <=20mg, pravastatin
<=20)

2

Medium potency: 25-30% LDL-C reduction (atorvastatin 10mg, simvastatin 20mg, fluvastatin 80mg, pravastatin 40)

3

High potency: is >30% LDL-C reduction (atorvastatin >=20mg, simvastatin >=40mg, fluvastatin 160mg, pravastatin
>=80, rosuvastatin >=5mg)
‡ Models adjusted for the same variables in the primary analysis. See tables 3a, 3b, 3c for specific variables.
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THIN TABLE 4
Table 4. Duration of response analysis for muscle toxicity, renal dysfunction, and hepatic dysfunction stratified
by statin 3A4 substrates and statin non-3A4 substrates with and without a CYP3A4 inhibitor (cyp).
Statin non-3A4
Events & P- Statin 3A4 substrate
IR/1000 Adjusted‡
substrate
Totals
p-y
years
I*R
cyp +
cyp cyp +
cyp 0-6
events
122
2520
7
211
2860
23.12
2.07
p-years
6509
104377
1019
11781
123685
Muscle
6-12
events
63
1082
10
89
1244
toxicity
9.89
0.72
p-years
6678
106370
1018
11772
125838
12-24
events
78
1264
8
137
1487
7.77
1.37
p-years
10988
160601
1629
18213
191431
>24
events
183
1822
24
269
2298
6.54
1.20
p-years
26433
285624
3561
35789
351408
0-6
events
22
198
3
19
242
2.63
0.96
p-years
4363
78150
710
8959
92183
Renal
6-12
events
17
153
3
12
185
2.00
0.60
dysfunction
p-years
4454
78550
699
8821
92524
12-24
events
30
210
5
25
270
1.94
0.89
p-years
7236
117080
1097
13524
138937
>24
events
106
558
14
74
752
3.00
0.99
p-years
17489
205049
2366
26035
250939
0-6
events
17
296
4
23
340
2.71
0.43
p-years
6702
105868
1061
11982
125614
Hepatic
6-12
events
11
172
2
15
200
1.56
0.65
dysfunction
p-years
6904
108304
1063
12035
128305
12-24
events
21
259
4
25
309
1.58
0.67
p-years
11387
164342
1704
18696
196130
>24
events
67
456
8
54
585
1.60
1.08
p-years
27964
296798
3796
37339
365897
‡ Models adjusted for the same variables in the primary analysis. See tables 3a, 3b, 3c for specific variables.
Outcome

Months
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95% CI
(0.95-4.49)
(0.36-1.44)
(0.65-2.89)
(0.79-1.87)
(0.26-3.51)
(0.15-2.33)
(0.32-2.51)
(0.54-1.82)
(0.13-1.38)
(0.13-3.19)
(0.21-2.09)
(0.49-2.36)

THIN TABLE 5
Table 5. Descriptive analysis of statin person-years and events with and without specific concomitant CYP3A4 inhibitors for muscle toxicity, renal dysfunction,
and hepatic dysfunction stratified by statin 3A4 substrates and statin non-3A4 substrates.
Muscle toxicity
Statin non-3A4
substrate

Statin 3A4 substrate

%†

Events

Statin w/o CYP3A4 inhibitor

657726

-

6688

77555

-

706

478830

-

1119

57339

-

130

675312

-

1183

80052

-

117

Statin w/ CYP3A4 inhibitor

50608

-

446

7227

-

49

33543

-

175

4872

-

25

52957

-

116

7624

-

18

36
7
1
2
3
-

25835
3548
2048
1481
545
321
63
76
68
33
27
18
3
1
0
0

85
67
10
7
2
6
2
1
-

3644
623
309
198
72
51
29
8
8
13
3
2
0
3
-

9
11
1
1
2
1
-

38558
7807
3361
2211
816
474
179
106
75
48
34
27
3
2
0
0

57
42
9
4
2
1
1
1
-

5318
1243
500
288
104
74
65
13
9
15
5
3
1
4
0

Events p-years

%†

Events p-years

%†

Statin non-3A4 substrate

%†

Events p-years

%†

Hepatic dysfunction
Statin 3A4 substrate

p-years

Events p-years

%†

Renal dysfunction
Statin non-3A4
substrate

Statin 3A4 substrate

Events p-years

Specific concomitant CYP3A4 inhibitors
330 5083
Diltiazem
36770 72.75
70.65
57
Amiodarone
7644
15.11
1214
16.78
22
Cimetidine
3218
6.37
483
6.71
29
Verapamil
2111
4.18
283
3.93
9
Erythromycin
777
1.54
98
1.36
4
Clarithromycin
447
0.88
70
0.98
2
Cyclosporine
183
0.36
66
0.92
1
Fluconazole
101
0.20
13
0.18
1
Fluvoxamine
80
0.16
9
0.13
Nefazadone
42
0.08
16
0.22
Itraconazole
34
0.07
5
0.07
Norfloxacin
23
0.05
3
0.04
Ketoconazole
3
0.01
1
0.01
Mibefradil
2
0.00
4
0.05
Imatinib
0
0.00
Voriconazole
0
0.00
0
0.00
† percent of total concomitant statin plus CYP3A4 inhibitor person-years

77.04
10.58
6.11
4.42
1.63
0.96
0.19
0.23
0.20
0.10
0.08
0.05
0.01
0.00
0.00
0.00
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74.88
12.81
6.35
4.08
1.48
1.06
0.59
0.17
0.17
0.26
0.06
0.04
0.00
0.06
-

73.05
14.79
6.37
4.19
1.55
0.90
0.34
0.20
0.14
0.09
0.07
0.05
0.01
0.00
0.00
0.00

70.89
16.57
6.66
3.84
1.39
0.99
0.87
0.18
0.13
0.19
0.07
0.04
0.01
0.05
0.00

11
7
1
-

DISSERTATION CONCLUSION
This research endeavor evaluated the clinical importance of the drug interaction between
statins and CYP3A4 inhibitors.

Two empiric investigations and a methodologic study were

conducted. The preliminary empiric study (the AERS study) showed an increased adverse event
reporting rate of rhabdomyolysis for simvastatin, a statin 3A4 substrate statin, with a concomitant
CYP3A4 inhibitor. There was no increased adverse event reporting rate for pravastatin, a statin
non-3A4 substrate, with a concomitant CYP3A4 inhibitor. These results supported observations
in clinical trials and case reports regarding increased risk of muscle toxicity for statin 3A4
substrates with concomitant CYP3A4 inhibitors. However, substantial limitations of internal
validity, inherent in spontaneous report analyses, warranted additional research to fully elucidate
these findings.
To assess the validity of the multinomial propensity score, we evaluated the statistical
performance of different propensity score methods in the setting of a simulated drug interaction
study. The results from this methodologic investigation showed the multinomial propensity score
reduced bias, had greater coverage probability, and increased precision than comparator binary
propensity score methods. Investigators studying drug-drug interactions may consider the
multinomial propensity score approach for confounding adjustment.
To further address the clinical importance of this drug interaction, we conducted a
retrospective cohort study in the THIN database (the THIN study).

This was the largest study

specifically designed to evaluate statin-related adverse events based on statin metabolism with
CYP3A4 inhibitor concomitancy. We used a multinomial propensity score to control confounding.
The results of this study showed no overall increased hazard for muscle toxicity, renal
dysfunction, or hepatic dysfunction associated with statin 3A4 substrates compared to statin non3A4 substrates with versus without a concomitant CYP3A4 inhibitor. We only identified a nonsignificant increased hazard of muscle toxicity for highly potent statin dosages and within six
months following statin initiation for statin 3A4 substrates compared to statin non-3A4 substrates.
Given the magnitude of this investigation, the drug interaction between statins and CYP3A4
inhibitors does not represent a substantial public health concern.
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